U.S. Stem Cell (USRM) 10-K 15 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 15, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	U.S. STEM CELL, INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		325,765,048
Entity Public Float			$ 114,186
Amendment Flag	false
Entity Central Index Key	1,388,319
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 270,720	$ 58,372
Accounts receivable, net	16,025	35,032
Inventory	42,218	17,406
Prepaid and other	0	4,832
Total current assets	328,963	115,642
Property and equipment, net	20,969	14,172
Other assets
Investments	67,544	89,139
Deposits	10,160	10,160
Total assets	427,636	229,113
Current liabilities:
Accounts payable, including $104,458 and $104,089 to related parties, respectively	1,290,292	1,503,501
Accrued expenses	904,772	726,751
Advances, related party	104,901	106,505
Deferred revenue	126,932	71,961
Deposits	465,286	465,286
Promissory note, short term portion, net of debt discount of $71,449 and $78,864 respectively	3,551	71,136
Notes payable, related party	2,290,285	1,727,022
Notes payable, net of debt discount of $103,479 and $249,205, respectively	680,336	608,502
Derivative liabilities	297,156	423,927
Total current liabilities	6,163,511	5,704,591
Long term debt:
Deferred revenue	71,500	0
Promissory note, long term portion, net of debt discount of $169,072 and $240,522, respectively	1,228,690	1,232,241
Notes payable, long term portion	982,579	983,727
Note payable, long term portion, related party	0	30,000
Total long term debt	2,282,769	2,245,968
Total liabilities	8,446,280	7,950,559
Commitments and contingencies	0	0
Stockholders’ deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding	20,000	20,000
Common stock, par value $0.001; 2,000,000,000 shares authorized, 127,012,740 and 1,813,689 shares issued and 127,012,740 and 1,728,478 outstanding as of December 31, 2016 and 2015, respectively	127,013	1,814
Additional paid in capital	115,981,103	114,555,110
Treasury stock, 0 and 85,211 shares as of December 31, 2016 and 2015, respectively	0	(221,996)
Accumulated deficit	(124,146,760)	(122,076,374)
Total stockholders’ deficit	(8,018,644)	(7,721,446)
Total liabilities and stockholders’ deficit	$ 427,636	$ 229,113

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounts payable, related parties (in Dollars)	$ 104,458	$ 104,089
Debt discount (in Dollars)	$ 103,479	$ 249,205
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	20,000,000	20,000,000
Preferred stock, shares outstanding	20,000,000	20,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	127,012,740	1,813,689
Common stock, shares outstanding	127,012,740	1,728,478
Treasury stock, shares	85,211
Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	$ 169,072	$ 240,522
Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	$ 71,449	$ 78,864

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Products	$ 1,827,355	$ 1,356,864
Services	1,255,906	834,313
Total revenue	3,083,261	2,191,177
Cost of sales	972,009	972,957
Gross profit	2,111,252	1,218,220
Cost and operating expenses:
Research and development	919	10,000
Marketing, general and administrative	3,264,107	3,808,628
Depreciation and amortization	5,785	5,326
Total operating expenses	3,270,811	3,823,954
Net loss from operations	(1,159,559)	(2,605,734)
Other income (expenses):
Gain on settlement of debt, net	53,690	2,620,233
Gain on disposal of equipment	500	0
Gain on change of fair value of derivative liability	56,244	15,095
Income from equity investment	153,405	38,542
Other income	10,975	13,282
Interest expense	(1,185,641)	(1,723,298)
Total other income (expenses)	(910,827)	963,854
Net loss before income taxes	(2,070,386)	(1,641,880)
Income taxes (benefit)	0	0
NET LOSS	$ (2,070,386)	$ (1,641,880)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.09)	$ (1.80)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	24,150,996	912,062

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]Common Stock [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]Common Stock [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]	Common Stock Issued in Settlement of Other Debt [Member]Common Stock [Member]	Common Stock Issued in Settlement of Other Debt [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Other Debt [Member]	Common Stock Issued for Settlement of Related Party Advances [Member]Common Stock [Member]	Common Stock Issued for Settlement of Related Party Advances [Member]Additional Paid-in Capital [Member]	Common Stock Issued for Settlement of Related Party Advances [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2014													$ 20,000	$ 581	$ 109,519,913	$ 0	$ (120,434,494)	$ (10,894,000)
Balance (in Shares) at Dec. 31, 2014													20,000,000	581,433
Common stock issued in settlement	$ 68	$ 236,818	$ 236,886	$ 24	$ 170,077	$ 170,101	$ 1,038	$ 2,818,666	$ 2,819,704
Common stock issued in settlement (in Shares)	67,944			24,353			1,037,645
Proceeds from issuance of common stock														$ 96	582,712			582,808
Proceeds from issuance of common stock (in Shares)														95,664
Common stock issued in settlement of litigation														$ 7	59,843			59,850
Common stock issued in settlement of litigation (in Shares)														6,650
Fair value of warrants issued															14,886			14,886
Purchase of shares of Company's common stock																(221,996)		(221,996)
Stock based compensation															1,152,195			1,152,195
Net loss																	(1,641,880)	(1,641,880)
Balance at Dec. 31, 2015													$ 20,000	$ 1,814	114,555,110	(221,996)	(122,076,374)	(7,721,446)
Balance (in Shares) at Dec. 31, 2015													20,000,000	1,813,689
Common stock issued in settlement	$ 2,464	$ 114,246	$ 116,710				$ 102,902	$ 1,083,885	$ 1,186,787	$ 14	$ 6,558	$ 6,572
Common stock issued in settlement (in Shares)	2,464,294						102,901,904			14,606
Proceeds from issuance of common stock														$ 19,914	40,086			60,000
Proceeds from issuance of common stock (in Shares)														19,913,708
Fair value of warrants issued																		0
Purchase of shares of Company's common stock																(7,817)		(7,817)
Treasury shares canceled and returned to authorized														$ (95)	(229,718)	229,813
Treasury shares canceled and returned to authorized (in Shares)														(95,461)
Change in fair value of repriced employee stock options															934			934
Stock based compensation															410,002			410,002
Net loss																	(2,070,386)	(2,070,386)
Balance at Dec. 31, 2016													$ 20,000	$ 127,013	$ 115,981,103	$ 0	$ (124,146,760)	$ (8,018,644)
Balance (in Shares) at Dec. 31, 2016													20,000,000	127,012,740

STATEMENT OF STOCKHOLDERS' EQU6

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Purchase of Company's Common Stock, Shares	10,250
Purchase of Company's Common Stock, Average Cost Per Share	$ 2.41
Common Stock [Member]
Purchase of Company's Common Stock, Shares	10,250	85,211
Purchase of Company's Common Stock, Average Cost Per Share	$ 0.76	$ 2.61

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,070,386)	$ (1,641,880)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,785	5,326
Bad debt expense	5,640	38,599
Discount on convertible debt	675,650	818,404
Change in fair value of derivative liability	(56,244)	(15,095)
Gain on settlement of debt	(53,690)	(2,620,233)
Gain on sale of equipment	(500)	0
Common stock issued in settlement of litigation	0	59,850
Related party notes payable issued for services rendered	800,000	0
Non cash payment of interest	193,946	528,915
Income on equity investments	(153,405)	(38,542)
Stock based compensation	410,002	1,152,195
Change in fair value of re-priced employee options	934	0
(Increase) decrease in:
Receivables	13,367	21,778
Inventory	(24,812)	(17,406)
Prepaid and other current assets	4,832	4,423
Accounts payable	10,464	434,490
Accrued expenses	224,188	365,525
Deferred revenue	126,471	58,961
Net cash provided by (used in) operating activities	112,242	(844,690)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from (payments to) equity investments	175,000	(10,000)
Proceeds from sale of property and equipment	500	0
Purchase of treasury stock	(7,817)	(221,996)
Acquisitions of property and equipment	(12,582)	(2,035)
Net cash provided by (used in) investing activities	155,101	(234,031)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net	60,000	582,808
Proceeds from notes payable	523,089	770,052
Net proceeds from related party advances	15,000	13,606
Repayments of related party notes	(266,737)	0
Repayments of notes payable	(386,347)	(266,047)
Net cash (used in) provided by financing activities	(54,995)	1,100,419
Net increase in cash and cash equivalents	212,348	21,698
Cash and cash equivalents, beginning of period	58,372	36,674
Cash and cash equivalents, end of period	270,720	58,372
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	65,522	321,846
Income taxes paid	0	0
Non-cash financing activities, stock issued	0	14,886
Common Stock Issued in Settlement of Notes Payable [Member]
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Non-cash financing activities, stock issued	497,312	926,381
Common Stock Issued in Settlement of Accounts Payable [Member]
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Non-cash financing activities, stock issued	255,686	236,886
Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member]
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Non-cash financing activities, stock issued	10,000	471,101
Common Stock Issued in Settlement of Guarantor Fees [Member]
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Non-cash financing activities, stock issued	0	170,101
Common Stock Issued in Exchange for Subordinated Debt and Accrued Expenses [Member]
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Non-cash financing activities, note issued	0	1,697,762
Common Stock Issued in Settlement of Legal Fees [Member]
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Non-cash financing activities, note issued	$ 0	$ 15,000

NOTE 1 - SIGNIFICANT ACCOUNTING

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying financial statements follows: Basis and business presentation U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise. On October 12, 2015, the Company amended its Articles of Incorporation to change its name from Bioheart, Inc. to U.S. Stem Cell, Inc. and to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of common stock. This amendment was approved and filed of record by the Florida Secretary of State on October 12, 2015, effective on October 19, 2015. FINRA has declared the Company’s 1-for-1,000 reverse stock split market effective as of November 4, 2015. In addition, the ticker symbol was BHRTD for 20 business days from November 4, 2015 at which point was changed to USRM. These financial statements have been retroactively restated to reflect the reverse stock split (see Note 10). Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from trainings are recognized when the training occurs. Any cash received as a deposit for trainings are recorded by the company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on vendor-specific objective evidence of fair value (VSOE). The multiple elements include stem cell banking, dose retrieval and yearly storage fees. At December 31, 2016 and 2015, the Company had deferred revenues of $198,432 and $71,961, respectively. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2016 and 2015, allowance for doubtful accounts was $12,487 and $-0-, respectively. Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs. Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting. (See Note 3) Long-Lived Assets The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company determined that there was no impairment on its long-lived assets during 2016 and 2015. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years. Income Taxes The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of derivative liability and stock compensation accounting versus tax differences. Comprehensive Income The Company does not have any items of comprehensive income in any of the periods presented. Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of December 31, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: 2016 2015 Convertible notes payable 238,046,980 677,540 Options to purchase common stock 23,555,777 555,820 Warrants to purchase common stock 139,145 139,367 Totals 261,741,902 1,372,727 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2016, there were outstanding stock options to purchase 23,555,777 shares of common stock, 8,380,503 shares of which were vested. (See Note 11) Treasury Stock The Company uses the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of December 31, 2016, four customers represented 45%, 13%, 13% and 12%, respectively, representing an aggregate of 83% of the Company’s accounts receivable. As of December 31, 2015, three customers represented 32%, 18% and 16% respectively, representing an aggregate of 66% of the Company’s accounts receivable. For the year ended December 31, 2016, the Company’s revenues earned from the sale of products and services to one customer, a related party, were $487,710, which represented 16% of the Company’s revenues. For the year ended December 31, 2015, the Company’s revenues earned from sale of products and services did not include any customers representing 10% or more of the Company’s total revenues. Reliance on Key Personnel and Consultants The Company has seven full-time employees and one part-time employee. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $919 and $10,000 for the years ended December 31, 2016 and 2015, respectively. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2016 and 2015, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2016 and 2015, the Company had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 7 and Note 9). Reclassification Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses. Recent Accounting Pronouncements There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during year ended December 31, 2016, the Company incurred net losses of $2,070,386 and as of December 31, 2016 has a working capital deficit of $5,834,548. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company’s primary source of operating funds in 2016 and 2015 has been from revenue generated from sales with additional cash proceeds from the sale of common stock and the issuance of convertible and other debt. The Company has experienced net losses from operations since inception, but expects these conditions to improve in 2017 and beyond as it develops its business model. The Company has stockholders’ deficiencies at December 31, 2016 and requires additional financing to fund future operations. The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

NOTE 3 - INVESTMENTS

NOTE 3 - INVESTMENTS	12 Months Ended
	Dec. 31, 2016
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 3 — INVESTMENTS The investment recorded is comprised of a 33% ownership of U.S. Stem Cell Clinic, LLC, accounted for using the equity method of accounting. The investments in 2014 and 2015 of cash and expenses paid on U.S. Stem Cell Clinic, LLC’s behalf were in aggregate of $59,714. The Company’s 33% income earned by U.S. Stem Cell Clinic, LLC was $153,405 and $38,542 for the year ended December 31, 2016 and 2015, respectively, (inception to date income of $182,830) was recorded as other income/expense in the Company’s Statement of Operations in the appropriate periods. In addition, during the year ended December 31, 2016, the Company received distributions totaling $175,000 from U.S. Stem Cell Clinic, LLC. The carrying value of the investment at December 31, 2016 and 2015 was $67,544 and $89,139, respectively. At December 31, 2016 and 2015, accounts receivable for sales of test kits to U.S. Stem Cell Clinic, LLC was $12,713 and $5,946 respectively; revenues earned from sales to U.S. Stem Clinic, LLC for the year ended December 31, 2016 and 2015 were $487,710 and $182,922, respectively.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2016 and 2015 is summarized as follows: 2016 2015 Laboratory and medical equipment $ 342,218 $ 353,253 Furniture, fixtures and equipment 130,410 130,410 Computer equipment 48,788 48,788 Leasehold improvements 362,046 362,046 883,462 894,497 Less accumulated depreciation and amortization (862,493 ) (880,325 ) $ 20,969 $ 14,172 Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives. During the year ended December 31, 2016, the Company sold fully depreciated equipment for net proceeds (and gain) of $500. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.

NOTE 5 - ACCRUED EXPENSES

NOTE 5 - ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 — ACCRUED EXPENSES Accrued expenses consisted of the following as of December 31, 2016 and 2015: 2016 2015 Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 154,296 $ 64,199 Interest payable on notes payable 599,510 467,664 Vendor accruals and other 146,429 147,244 Employee commissions, compensation, etc. 4,537 47,644 $ 904,772 $ 726,751 During the year ended December 31, 2016, the Company issued an aggregate of 2,464,294 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $138,976 net gain in settlement of debt. During the year ended December 31, 2015, the Company issued an aggregate of 67,944 shares of its common stock in settlement of outstanding accounts payable and accrued interest. In connection with the issuance, the Company incurred $144,669 gain in settlement of debt. During the year ended December 31, 2015, the Company incurred a gain of $513,940 in relief of accounts payable. During the year ended December 31, 2015, the Company issued an aggregate of 24,353 shares of its common stock in settlement of accumulative outstanding amounts due to Guarantors of the Company of $961,124. In connection with the issuance, the Company incurred a $791,024 gain in settlement of debt. During the year ended December 31, 2015, the Company settled an outstanding subordinated debt, related accrued interest and accounts payable due to the guarantor by issuing a five year, non-interest bearing note payable. (See Note 7). In connection with the note issuance, the Company settled $624,737 of outstanding guarantor fees.

NOTE 6 - STOCK PURCHASE AGREEME

NOTE 6 - STOCK PURCHASE AGREEMENT	12 Months Ended
	Dec. 31, 2016
Stock Purchase Agreement Disclosure [Abstract]
Stock Purchase Agreement Disclosure [Text Block]	NOTE 6 – STOCK PURCHASE AGREEMENT On October 23, 2014, the Company, entered into a common stock purchase agreement (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (the “Investor”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, the Investor is committed to purchase up to $3,000,000 (the “Total Commitment”) worth of the Company’s common stock, $0.001 par value (the “Shares”), over the 24-month term of the Purchase Agreement. From time to time over the term of the Purchase Agreement, commencing on the trading day immediately following the date on which the initial registration statement was declared effective by the Securities and Exchange Commission (the “Commission”), the Company may provide the Investor with a draw down notice to purchase a specified dollar amount of Shares, with each draw down subject to certain limitations. The Company may not deliver any Draw Down Notice to the Investor if the Initial Purchase Price with respect to the Shares subject to such Draw Down Notice is less than $2.50 as of the date the applicable Draw Down Notice is received by the Investor (the “Draw Down Exercise Date”). The applicable Initial Purchase Price, the “Initial Purchase Price”, is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company’s common stock (the “ VWAP In 2014, the Company paid to the Investor as a commitment fee for entering into the Purchase Agreement equal an aggregate of to 12,000 shares of the Company’s common stock. During the year ended December 31, 2015, the Company issued an aggregate of 87,812 shares of its common stock in exchange for $521,538 under the Purchase Agreement. (See Note 10)

NOTE 7 - NOTES PAYABLE

NOTE 7 - NOTES PAYABLE	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 7 — NOTES PAYABLE Promissory notes payable were comprised of the following as of December 31, 2016 and 2015: 2016 2015 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams notes payable 384,972 384,972 Daniel James Management notes payable 7,940 75,000 Fourth Man, LLC notes payable 100,000 77,450 Magna Group notes payable 130,455 125,000 Power Up Lending Group notes payable 159,300 194,235 Equipment finance lease 3,727 4,777 Total notes payable 1,766,394 1,841,434 Less unamortized debt discount (103,479 ) (249,205 ) Total notes payable net of unamortized debt discount 1,662,915 1,592,229 Less current portion (680,336 ) (608,502 ) Long term portion $ 982,579 $ 983,727 Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2016 to extend the maturity date to January 11, 2018. Hunton & Williams Notes At December 31, 2016 and 2015, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off. Asher Notes 2015 Notes During the year ended December 31, 2015, the Company entered into Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $180,000 (the “Asher Notes”). The Company incurred legal fees in the amount of $15,000 which were deducted from the proceeds of the notes. The Asher Notes bear interest at the rate of 8% per annum. As of the year ended December 31, 2015, all interest and principal must be repaid nine months from the issuance date, with the last note being due February 6, 2016. The Asher Notes are convertible into shares of common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the shares of common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes (See Note 9). These embedded derivatives included certain conversion features and a reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date, which at December 31, 2015 was $-0- (all Notes converted). At the inception of the Asher Notes, the Company determined the aggregate fair value of $211,575 of the embedded derivatives. During the year ended December 31, 2015, $151,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $180,000 of notes plus accrued interest that were issued during 2015, was converted into shares of the Company’s common stock (See Note 10). The remaining aggregate Asher Notes unconverted principle balance as of December 31, 2015 was $-0-. Daniel James Management 2015 Notes During the year ended December 31, 2015, the Company entered into Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 9.5% convertible note in aggregate principal amount of $125,000 (the “Daniel Notes”). The Daniel Notes bear interest at the rate of 9.5% per annum. As of the year ended December 31, 2015, all interest and principal must be repaid one year from the issuance date, with the last note being due October 29, 2016. The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Notes. These embedded derivatives included certain conversion features and reset provision. (See Note 9). The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Notes and to fair value as of each subsequent reporting date which at December 31, 2015 was $120,263. At the inception of the Daniel Notes, the Company determined the aggregate fair value of $238,443 of the embedded derivatives. During the year ended December 31, 2015, $75,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $50,000 of notes plus accrued interest that were issued during 2015, were converted into shares of the Company’s common stock (See Note 10). The remaining aggregate Daniel Notes unconverted principle balance as of December 31, 2015 was $75,000. 2016 Notes During the year ended December 31, 2016, the Company entered into Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 9.5% convertible promissory note in aggregate principal amount of $75,000 (the “Daniel Notes”). The Daniel Notes bear interest at the rate of 9.5% per annum. As of the year ended December 31, 2016, all interest and principal must be repaid one year from the issuance date, with the last note being due March 9, 2017. The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Notes. These embedded derivatives included certain conversion features and reset provision. (See Note 9) The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Notes and to fair value as of each subsequent reporting date which at December 31, 2016 was $9,436. At the inception of the Daniel Notes, the Company determined the aggregate fair value of $139,691 of the embedded derivatives. During the year ended December 31, 2016, $75,000 of promissory notes plus accrued interest that were outstanding at December 31, 2015 and $67,060 of promissory notes plus interest issued in the current year were converted into shares of the Company’s common stock, respectively (See Note 10). The remaining aggregate promissory notes to Daniel unconverted principle balance as of December 31, 2016 was $7,940. The remaining unamortized debt discount at December 31, 2016 was $1,483. Fourth Man, LLC 2015 Notes During the year ended December 31, 2015, the Company entered into Securities Purchase Agreements with Fourth Man, LLC. (“Fourth Man”) for the sale of a 9.5% convertible notes in the aggregate principal amount of $150,000 (the “Notes”). The Notes bears interest at the rate of 8% to 9.5% per annum. As of the year ended December 31, 2015, all interest and principal must be repaid one year from the issuance date, with the last note being due December 2, 2016. The Notes are convertible into shares of common stock, at Fourth Man’s option, at a 47% discount to the lowest closing bid price of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Notes. These embedded derivatives included certain conversion features and reset provision. (See Note 9) The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Notes and to fair value as of each subsequent reporting date which at December 31, 2015 was $126,825. At the inception of the Fourth Man Notes, the Company determined the aggregate fair value of $356,225 of the embedded derivatives. During the year ended December 31, 2015, $75,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $72,550 of notes plus accrued interest that were issued during 2015, were converted into shares of the Company’s common stock (See Note 10). The remaining aggregate Fourth Man, LLC Notes unconverted principle balance as of December 31, 2015 was $77,450. 2016 Notes During the year ended December 31, 2016, the Company entered into Securities Purchase Agreements with Fourth Man, LLC (“Fourth Man”) for the sale of 9.5% convertible promissory note in aggregate principal amount of $100,000 (the “Fourth Man Notes”). The Fourth Man Notes bear interest at the rate of 9.5% per annum. As of the year ended December 31, 2016, all interest and principal must be repaid one year from the issuance date, with the last note being due September 19, 2017. The Fourth Man Notes are convertible into common stock, at holder’s option, at a 49% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Notes. These embedded derivatives included certain conversion features and reset provision. (See Note 9) The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Notes and to fair value as of each subsequent reporting date which at December 31, 2016 was $151,236. At the inception of the Fourth Man Notes, the Company determined the aggregate fair value of $216,050 of the embedded derivatives. During the year ended December 31, 2016, $77,450 of promissory notes plus accrued interest that were outstanding at December 31, 2015 were converted into shares of the Company’s common stock (see Note 10). The remaining aggregate promissory notes to Fourth Man unconverted principle balance as of December 31, 2016 were $100,000. The remaining unamortized debt discount at December 31, 2016 is $53,503. Magna Group 2015 Notes On October 1, 2015, the Company entered into a securities purchase agreement with Magna Equities II, LLC. The purchase agreement provides that Magna shall purchase from the Company on the closing date a senior convertible note with an initial principal amount of $110,000 for a purchase price of $100,000. The Note bears interest at the rate of 12% per annum. All interest and principal must be repaid on August 1, 2016. The convertible note is convertible at any time, in whole or in part, at Magna’s option into shares of the Company’s common stock at a the lower of i) 60% discount to the lowest trading price of the common stock during the 5 trading day period prior to conversion or ii) $0.70 per share. On December 3, 2015, the Company entered into a convertible promissory note with Magna Equities II, LLC. The note provides that Magna shall pay on the Company’s behalf certain accrued legal fees of $15,000. The December 3, 2015 convertible note bears interest at the rate of 12% per annum. All interest and principal must be repaid on August 1, 2016. The convertible note is convertible at any time, in whole or in part, at Magna’s option into shares of the Company’s common stock at the lower of 60% of the lowest sale price of the Company’s common stock during five trading days preceding conversion date or $0.70 per share (subject to adjustment). The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Magna Notes and to fair value as of each subsequent reporting date which at December 31, 2015 was $164,600. At the inception of the Magna Note, the Company determined the aggregate fair value of $291,136 of the embedded derivatives. During the year ended December 31, 2015, $205,000 of note that were outstanding at December 31, 2014, plus accrued interest, were converted into shares of the Company’s common stock (See Note 10). The remaining Magna notes principle balance as of December 31, 2015 was $125,000. 2016 Notes On December 3, 2015, the Company entered into a Securities Purchase Agreement with Magna Equities II, LLC (“Magna”) for the sale of a 12% convertible promissory note in the principal amount of $262,500 (the “Note”). The Note was subsequently funded in February 2016 upon effectiveness of the Company’s registration statement (see below). Proceeds from the Note were $250,000 (less an original issue discount of 5% or $12,500). The Note bears interest at the rate of 12% per annum. All interest and principal must be repaid on December 3, 2016. The Note is convertible into common stock, at Magna’s option, at the lower of I) 40% discount to the lowest sales price of the common stock during the 5 trading day period prior to conversion or ii) $0.70. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 140%, interest and any other amounts. On December 12, 2015, the Company filed a Registration Statement on Form S-1 to register 341,718 shares of common issuable upon the conversion of Magna Equity II, LLC convertible notes dated December 3, 2015 (as restated) for $110,000 and December 3, 2015 for $262,500. The latter note was funded in February 2016. The Registration Statement on Form S-1 was declared effective on February 12, 2016 The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Notes to Magna and to fair value as of each subsequent reporting date which at December 31, 2016 was $136,460. At the inception of the Notes, the Company determined the aggregate fair value of $263,204 of the embedded derivatives. During the year ended December 31, 2016, $257,045 of the promissory notes were converted into shares of the Company’s common stock (See Note 9). The remaining aggregate Magna Group promissory notes unconverted principle balance as of December 31, 2016 was $130,455. PowerUp Lending Group, Ltd 2015 Note In July 2015, the Company entered into two revenue based factoring agreements and received an aggregate of $180,000 (less origination fees of $3,590) in exchange for $243,000 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreements, the Company is required to make daily payments equal to the greater of $1,464 or 20% of the Company’s daily cash or monetary sales receipts over the term of the agreements (ranging from 126 to 189 business days). The Company has recorded a debt discount which is being amortized to interest expense over the term of the agreements. On December 17, 2015, the Company entered into a revenue based factoring agreement and received an aggregate of $150,000 (less origination fees of $4,500) in exchange for $202,500 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreements, the Company is required to make daily payments equal to $1,378 for 147 business days. The Company received net proceeds of $53,642 along with cancellation of the previous two revenue based factoring agreements described above. In connection with the cancellation of the July 2015 revenue based factoring agreements, the Company incurred a loss in settlement of debt of $8,679. The remaining principle balance of the PowerUp Lending Group notes payable at December 31, 2015 is $194,235 At December 31, 2015, the Company has recorded interest expense in the amount of $44,226 under the terms of the agreements. The remaining unamortized debt discount at December 31, 2015 is $51,164. 2016 Notes On March 23, 2016, the Company entered into a revenue based factoring agreement and received an aggregate of $200,000 (less origination fees of $1,650) in exchange for $276,000 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreement, the Company is required to make daily payments equal to $1,314 for 210 business days. The Company received net proceeds of $82,896 along with cancellation of the previous revenue based factoring agreement issued in 2015. In connection with the cancellation of the December 2015 revenue based factoring agreement, the Company incurred a loss in settlement of debt of $39,449. On August 16, 2016, the Company entered into a revenue based factoring agreement and received an aggregate of $210,000 (less origination fees of $2,000) in exchange for $283,500 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreement, the Company is required to make daily payments equal to $1,350 for 210 business days. The Company received net proceeds of $65,193 along with cancellation of the previous revenue based factoring agreement issued on March 23, 2016. In connection with the cancellation of the March 2016 revenue based factoring agreement, the Company incurred a loss in settlement of debt of $49,264. The remaining principle balance of the PowerUp Lending Group promissory note payable at December 31, 2016 is $159,300. At December 31, 2016, the Company has recorded interest expense in the amount of $27,007 under the terms of the agreement. The remaining unamortized debt discount at December 31, 2016 is $48,493. Promissory note On June 1, 2015, the Company issued an amended and restated promissory note of $1,697,762 in settlement of the $1,500,000 outstanding subordinated debt, related accrued interest of $373,469 and accumulated and unpaid guarantor fees of $624,737. The note is unsecured and non-interest bearing with four semi-annual payments of $75,000 beginning on December 31, 2015 with the remaining unpaid balance due June 1, 2020. The Company imputed an interest rate of 5% and discounted the promissory note accordingly. The imputed debt discount of $368,615 is amortized to interest expense using the effective interest method. For the year ended December 31, 2016 and 2015, the Company amortized $78,864 and $49,229 of debt discounts to current period operations as interest expense, respectively. The unamortized debt discount at December 31, 2016 is $240,521. In connection with the settlement, the Company recorded a gain on settlement of debt of $1,169,058 during the year ended December 31, 2015. During 2016 and 2015, the Company made principle payments of $150,000 and $75,000 on the promissory note, respectively. As of December 31, 2016, the remaining principle due was $1,472,762. Summary: The Company has identified the embedded derivatives related to the Asher, Daniel, Fourth Man and Magna promissory notes. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date which at December 31, 2016 was $297,132. The fair value of the embedded derivatives at issuance of the Daniel, Fourth Man and Magna promissory notes, were determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 178.42% to 213.94%, (3) weighted average risk-free interest rate of 0.45% to 0.69%, (4) expected lives of 0.79 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $0.0145 to $0.9342 per share. The initial fair value of the embedded debt derivative of $618,946 was allocated as a debt discount up to the proceeds of the notes ($425,000) with the remainder ($193,946) charged to current period operations as interest expense. For the year ended December 31, 2016 and 2015, the Company amortized an aggregate of $596,786 and $768,241 of debt discounts to current period operations as interest expense, respectively.

NOTE 8 - RELATED PARTY TRANSACT

NOTE 8 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 — RELATED PARTY TRANSACTIONS Advances As of December 31, 2016 and 2015, the Company’s officers and directors have provided advances in the aggregate of $104,901 and $106,505 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing. On November 4, 2015, the Company issued 3,411 shares of common stock in settlement of $5,860 of related party advances. On February 12, 2016, the Company issued 14,606 shares of its common stock in settlement of $10,000 of the outstanding advances due. In connection with the settlement, the Company realized a net gain on settlement of debt of $3,427. Notes payable-related party Northstar Biotechnology Group, LLC On February 29, 2012, a promissory note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267 the (“Note”). On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock. On September 21, 2012, the Company issued 5,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance. On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum. In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties agreed to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company and the preferred shareholder are in litigation regarding the number of votes currently held by that shareholder (See Note 10). As described above, during the year ended December 31, 2013, the Company issued the 5,000,000 shares of Series a Convertible Preferred Stock and the 10,000 of common stock described above in exchange for the $210,000 as payment towards outstanding principle of the debt. In addition, the Company issued 15,000,000 shares of Series A Convertible Preferred Stock as a penalty in settlement of the terms of the forbearance agreement. The fair value of the Preferred Stock of $274,050 was included in interest expense for the year ended December 31, 2013. On September 30, 2013, the Company issued 8,772 shares of its common stock as payment of $100,000 towards cash advances. On December 24, 2013, the Company issued 3,916 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447. On April 2, 2014, the Company issued 275 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement. On September 17, 2014, limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such to condition upon NorthStar providing certain financing, which financing the Company, in its sole discretion, could decline and retain the license. On October 3, 2014, the Company issued 515 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement. On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement. On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement. On October 7, 2015, the Company issued 34,522 shares of its common stock in settlement of $100,000 principal payment towards the outstanding debt. On April 7, 2016, the Company issued 57,778 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due April 1, 2016 per the forbearance agreement. On October 6, 2016, the Company issued 848,490 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2016 per the forbearance agreement. As of December 31, 2016 and 2015, the principal of this note was $262,000. U.S Stem Cell Clinic On November 6, 2015, the Company issued a 4% promissory note to U.S. Stem Cell Clinic for $30,000 due November 3, 2017. During 2016, the Company paid off the amount in full. Officer and Director Notes 2016 2015 Note payable, Beverly Murphy $ 50,000 $ 50,000 Note payable, Mr. Tomas 81,420 252,250 Note payable, Mr. Tomas 375,000 375,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 - Note payable, Ms. Comella 221,865 287,772 Note payable, Ms. Comella 300,000 - Total $ 2,028,285 $ 1,465,022 Notes payable, Dr. Murphy On November 4, 2015, the Company issued 270,800 shares of common stock in settlement of $465,200 of outstanding notes payable to Dr. Murphy. Note payable, Ms. Murphy At December 31, 2016 and 2015, the Company has outstanding promissory note payable of $50,000 due to Beverly Murphy with interest at 7% per annum due at maturity at October 15, 2015. Notes payable, Mr. Tomas In 2013, the Company issued a promissory note payable for previous advances and accrued compensation. The promissory note bears interest of 5% per annum and due on demand. During the years ended December 31, 2016 and 2015, the Company paid off $170,830 and $79,104 of the outstanding promissory note, respectively. The principal outstanding balance of this note as of December 31, 2016 and 2015 was $81,420 and $252,250, respectively. On August 1, 2013, the Company issued a $375,000 promissory note due on demand in settlement of accrued compensation. The promissory note bears interest of 5% per annum and is due on demand. The principal outstanding balance of this note as of December 31, 2016 and 2015 was $375,000. On July 1, 2014, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and was due on January 1, 2015. The principal outstanding balance of this note as of December 31, 2016 and 2015 was $500,000. On September 6, 2016, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and is due upon demand. The principal outstanding balance of this note as of December 31, 2016 was $500,000. Notes payable, Ms. Comella On July 1, 2014, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and due on January 1, 2015. During the years ended December 31, 2016 and 2015, the Company paid off $65,907 and $11,693 of the outstanding promissory note, respectively. The principal outstanding balance of this promissory note as of December 31, 2016 and 2015 was $221,865 and $287,772, respectively. On September 6, 2016, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and was due upon demand. The principal outstanding balance of this note as of December 31, 2016 is $300,000. Transactions with Pavillion During the year ended December 31, 2016 and 2015, the Company purchased $-0- and $242,271 of lab kits from Pavillion, Inc., a related party whose owner is related to an officer of the Company. As of December 31, 2016 and 2015, the Company had $106,455 and $74,793, respectively, in accounts payable owed to Pavillion. On May 1, 2016, the Company entered into a consulting agreement with Pavillion. The agreement is for 12 months and renewable for 6 month periods. Compensation is at $250 per hour or, at the Company’s discretion, in shares of the Company’s common stock. For the year ended December 31, 2016, the Company has incurred $80,000 under the agreement.

NOTE 9 - DERIVATIVE LIABILITIES

NOTE 9 - DERIVATIVE LIABILITIES	12 Months Ended
	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 9 — DERIVATIVE LIABILITIES Reset warrants On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 7, the Company issued an aggregate of 15,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $14.00 per share for ten years with anti-dilutive (reset) provisions. The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date. At December 31, 2016, the fair value of the reset provision related to the embedded derivative liability of $24 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 232.12%; risk free rate: 1.93%; and expected life: 5.75 years. The Company recorded a gain on change in derivative liabilities of $12,185 and $137,710 during the years ended December 31, 2016 and 2015, respectively. Convertible notes In 2016 and 2015, the Company issued convertible promissory notes (See Note 7). These promissory notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these promissory notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date. The fair value of the embedded derivatives at December 31, 2016, in the amount of $297,132, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 232.12%, (3) weighted average risk-free interest rate of 0.51% to 0.62%, (4) expected lives of 0.19 to 0.72 years, and (5) estimated fair value of the Company’s common stock of $0.0019 per share. The Company recorded a gain (loss) on change in derivative liabilities of $44,059 and $(122,615) during the years ended December 31, 2016 and 2015. Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible promissory notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

NOTE 10 - STOCKHOLDERS' EQUITY

NOTE 10 - STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 10 — STOCKHOLDERS’ EQUITY Preferred stock On August 17, 2012, the Board of Directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock (currently held by Northstar Biotechnology Group, LLC). Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar on April 1, 2013 and October 1, 2013, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 8). During the year ended December 31, 2013, the Company issued an aggregate of 20,000,000 shares of Series A Convertible Preferred Stock for principle payment and settlement of forbearance (see note 8 above). Common stock On October 12, 2015, the Company filed an amendment to its Articles of Incorporation and affected a 1-for-1,000 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, and effective November 19, 2015. The Financial Industry Regulatory Authority (“FINRA”) declared the ex-dividend date for the dividend date as November 4, 2015. All per share amounts and number of shares in the financial statements and related notes have been retroactively restated to reflect the reverse stock split as if it had occurred on the first day of the first period presented resulting in the transfer of $580,852 from common stock to additional paid in capital at December 31, 2014. During the year ended December 31 2016, the Company issued an aggregate of 102,901,904 shares of its common stock for the conversion of $497,312 of promissory notes payable and related accrued interest. Upon conversion of the notes, the Company recorded an adjustment to the derivative liability in the amount of $689,473 (See Note 14). During the year ended December 31, 2016, the Company purchased 10,250 shares of the Company’s common stock in the open market at an average cost of $0.76 per share. During the year ended December 31, 2016, the Company returned and canceled 95,461 shares of the Company’s common stock previously purchased (treasury shares) at an average cost of $2.41 per share. On February 12, 2016, the Company issued 14,606 shares of its common stock in settlement of $10,000 of the outstanding advances due. In connection with the settlement, the Company realized a net gain on settlement of debt of $3,427 (See Note 8). On April 7, 2016, the Company issued 57,778 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement on Northstar note (See Note 8). On October 6, 2016, the Company issued 848,490 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement on Northstar note (See Note 8). During the year ended December 31, 2016, the Company issued an aggregate of 1,558,026 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $138,976 net gain in settlement of debt. During the year ended December 31, 2016, the Company issued 19,913,708 shares of common stock for $60,000. During the year ended December 31, 2015, the Company issued an aggregate of 62,425 shares of its common stock in the amount of $211,546 for the settlement of outstanding accounts payable and accrued expenses. In connection with the issuance of the shares the Company recognized a gain on settlement of accounts payable and accrued expenses in the amount of $144,669 (see Note 5). During the year ended December 31, 2015, the Company issued 6,650 shares of common stock in settlement of litigation. In connection with the issuances, the Company recognized a loss in the amount of $59,850, which is included in the marketing, general and administration expense in the Statement of Operations (see Note 12). On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement on Northstar note (See Note 8). On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement on Northstar note (See Note 8). During the year ended December 31, 2015, the Company issued an aggregate of 763,434 shares of its common stock for the conversion of $949,017 of notes payable and related accrued interest. Upon conversion of the notes, the Company recorded an adjustment to the derivative liability in the amount of $1,399,628 (see Note 14). On November 4, 2015, the Company issued 270,800 shares of common stock in settlement of $465,200 of outstanding notes payable to Dr. Murphy. On November 4, 2015, the Company issued 3,411 shares of common stock in settlement of $5,860 of related party advances. During the year ended December 31, 2015, the Company purchased 85,211 shares of the Company’s common stock in the open market at an average cost of $2.61 per share. During the year ended December 31, 2015, the Company issued an aggregate of 87,812 shares of common stock in exchange for $521,538 under the stock purchase agreement with Magna Equities II, LLC, and issued an aggregate of 7,852 shares of common stock in exchange for $61,270. In connection with the stock sale, the Company issued an aggregate of 1,444 warrants to purchase the Company’s common stock (see Note 11). During the year ended December 31, 2015, the Company issued an aggregate of 24,353 shares of its common stock in settlement of accumulative outstanding amounts due to Guarantors of the Company of $961,125. In connection with the issuance, the Company incurred a $791,024 gain in settlement of debt.

NOTE 11 - STOCK OPTIONS AND WAR

NOTE 11 - STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 11 — STOCK OPTIONS AND WARRANTS Stock Options In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011. On April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the U.S. Stem Cell Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty thousand shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred thousand shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan. On February 2, 2015, at the annual meeting of shareholders, the majority of shareholders approved the 2013 Omnibus Equity Compensation Plan. On November 2, 2015, the Board of Directors approved the increase of the reserve under the 2013 Omnibus Plan to five hundred million shares of common stock for issuance and effective September 16, 2016, approved an addition of twenty five million shares of common stock to the reserve. A summary of options at December 31, 2016 and activity during the two years then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at January 1, 2015 66,933 $ 56.00 8.9 Granted 489,116 $ 1.98 10.0 Exercised — Forfeited/Expired (229 ) $ 5,103.28 Options outstanding at December 31, 2015 555,820 $ 6.43 9.6 Granted 23,000,000 $ 0.02 10.0 Exercised — Forfeited/Expired (43 ) $ 1,960.39 Options outstanding at December 31, 2016 23,555,777 $ 0.03 9.7 Options exercisable at December 31, 2016 8,380,503 $ 0.06 9.7 Available for grant at December 31, 2016 9,383,070 The following information applies to options outstanding and exercisable at December 31, 2016: Exercise Number Option Outstanding Options Average Remaining Contractual Life (years) Weighted Average Number Options Exercisable Weighted Average Exercise price $ 0.0196 22,850,000 9.72 $ 0.0196 7,850,000 $ 0.0196 0.15402 705,412 8.74 0.15402 530,213 0.15402 19.32 150 7.85 19.32 75 19.32 70.00 100 4.66 70.00 100 70.00 210.00 40 4.62 210.00 40 210.00 680.00 40 3.11 680.00 40 680.00 5,250.00 35 1.30 5,250.00 35 5,250.00 Total 23,555,777 9.69 $ 0.033 8,380,503 $ 0.05529 On April 18, 2016, the Company granted an aggregate 150,000 options to purchase the Company’s common stock at $0.15402 per share to key employees, vesting over 4 years, at grant date anniversary and exercisable over 10 years. The aggregate fair value of $10,928, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 184.48% and Risk free rate: 1.54%. On April 18, 2016, the Company re-priced an aggregate of 555,433 previously issued options with exercise prices from $1.71 to $7,688.83 per share to $0.15402 per share. All other terms and conditions were unchanged. The aggregate change in fair value of $934, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 184.48% and Risk free rate: 0.22% to 1.78%, was charged to current period operations. On September 19, 2016, the Company granted an aggregate 22,850,000 options to purchase the Company’s common stock at $0.0196 per share to officers, directors and key employees with 15,000,000 vesting over 4 years, at grant date anniversary and 7,850,000 vesting immediately; for a term of 10 years. The aggregate fair value of $347,706, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 213.30% and Risk free rate: 1.22%. On February 2, 2015, the Company granted an aggregate 7,000 options to purchase the Company’s common stock at $11.16 per share to members of the Board of Directors, vesting immediately and exercisable over 10 years. The aggregate fair value of $121,735, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 142.65% and Risk free rate: 1.68%. On August 24, 2015, the Company granted 100 options to purchase the Company’s common stock at $5.31 per share to a consultant, vesting immediately and exercisable over 4 years. The aggregate fair value of $347, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 129.01% and Risk free rate: 1.39%. On November 2, 2015, the Company granted an aggregate of 467,016 options to purchase the Company’s common stock at $1.713 per share to two officers, vesting immediately and exercisable over 10 years. The aggregate fair value of $738,405 determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 160.66% and Risk free rate: 1.57%. On November 2, 2015, the Company granted an aggregate of 15,000 options to purchase the Company’s common stock at $6.24 per share to two officers, vesting over four years on each anniversary and exercisable over 10 years. The aggregate fair value of $23,512, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 160.66% and Risk free rate: 1.93%. The fair value of all options vesting during the year ended December 31, 2016 and 2015 of $410,385 and $1,156,435, respectively, was charged to current period operations. As of December 31, 2016, the Company had approximately $438,472 of total unrecognized compensation cost related to non-vested awards granted under the Plan, which the Company expects to recognize over a weighted average period of 1.33 years. Warrants A summary of common stock purchase warrants at December 31, 2016 and activity during the two years ended December 31, 2016 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at January 1, 2015 150,620 $ 170.00 6.6 Issued 2,072 $ 19.98 8.18 Exercised - Expired (13,325 ) $ 24.00 Outstanding at December 31, 2015 139,367 $ 182.26 6.3 Issued - Exercised - Expired (222 ) $ 5,966.40 Outstanding at December 31, 2016 139,145 $ 173.03 5.5 Exercisable at December 31, 2016 135,600 $ 89.42 5.5 The following information applies to common stock purchase warrants outstanding and exercisable at December 31, 2016: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 6.0 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 5.1 $ 24.52 28,743 $ 24.62 $ 30.01 – $40.00 628 0.6 $ 40.00 628 $ 40.00 $ 40.01 - $50.00 6,253 2.9 $ 48.36 5,253 $ 48.41 $ 50.01 – $60.00 543 4.6 $ 60.00 543 $ 60.00 $ >60.00 7,870 3.3 $ 2,735.01 6,325 $ 1,524.67 139,145 5.5 $ 173.03 135,600 $ 89.42 During the year ended December 31, 2015, the Company issued 628 warrants in connection with the settlement of debt. The warrants are exercisable at $40.00 for three years. The fair value of $14,886, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 164.06% and Risk free rate: 0.87%. In connection with the settlement, the Company recorded a gain of $10,221 in settlement of debt to current period operations.

NOTE 12 - COMMITMENTS AND CONTI

NOTE 12 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 12 — COMMITMENTS AND CONTINGENCIES Leases On February 4, 2016, the Company amended its facility lease to extend the term of the lease until August 31, 2019. Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of December 31, 2016 are as follows: Period ending December 31, 2017 87,674 2018 87,674 2019 58,448 Total $ 233,796 Employment agreements On July 28, 2014, the Company’s Board of Directors approved the 2014/2015 salary for Mike Tomas, Chief Executive Officer, at $525,000 per year, beginning July 1, 2014 with an incentive bonus ranging from $150,000 to $500,000. In addition, the Board of Directors will grant Mr. Tomas options to be determined on or before June 30, 2015. The Company’s Board of Directors approved a bonus of $500,000 and options to acquire 10,000 shares of the Company’s common stock for ten years with four year vesting and a cashless exercise provision at an exercise price equal to the five day average closing price of the Company’s common stock as of August 1, 2014. The cash bonus may be paid in the form a six month promissory note. On November 2, 2015, the Company granted Mr. Tomas - 291,885 options to acquire the Company’s stock with an exercise price of $1.713 per share, vesting immediately and expiring ten years from the date of issuance. On September 6, 2016, the Company’s Board of Directors approved a cash bonus of $500,000 that will accrue interest at 5% per annum until paid. In addition, the Company granted Mr. Tomas 10,000,000 options to acquire the Company’s stock with an exercise price of $0.0196, vesting over four years on the anniversary and expiring ten years from the date of issuance. On July 28, 2014, the Company’s Board of Directors approved the 2014/2015 salary for Kristin Comella, Chief Scientific Officer, at $250,000 per year, beginning July 1, 2014 with an incentive bonus ranging from $100,000 to $300,000. In addition, the Board of Directors will grant Ms. Comella options to be determined on or before June 30, 2015. The Company’s Board of Directors approved a bonus of $300,000 and options to acquire 5,000 shares of the Company’s common stock for ten years with four year vesting and a cashless exercise provision at an exercise price equal to the five day average closing price of the Company’s common stock as of August 1, 2014. The cash bonus may be paid in the form a six month promissory note. On November 2, 2015, the Company granted Ms. Comella 175,131 options to acquire the Company’s stock with an exercise price of $1.713 per share, vesting immediately and expiring ten years from the date of issuance. On September 6, 2016, the Company’s Board of Directors approved a cash bonus of $300,000 that will accrue interest at 5% per annum until paid. In addition, the Company granted Ms. Comella 5,000,000 options to acquire the Company’s stock with an exercise price of $0.0196, vesting over four years on the anniversary and expiring ten years from the date of issuance. Royalty Agreement On November 9, 2016, the Company entered into an Intellectual Property License Agreement whereby the Company granted High Rise Group Company the exclusive right to the Company’s intellectual property (as defined) for the licensed use and development in Middle East for 25 years in exchange for a payment of $75,000 and a 5% royalty generated under the agreement. Litigation On March 19 2015, the Company settled a prospective dispute with a third party over the use of proprietary information through the issuance of 6,650 shares of common stock. (See Note 10) On September 17, 2015, a product liability lawsuit was filed in Broward County, specifically Patsy Bade v. Bioheart, Inc. US Stem Cell Clinics LLC, Aleiandro Perez, ARNP, and Shareen Greenbaum, M.D., and on November 30, 2015, a product liability lawsuit was filed in Broward County, specifically Elizabeth Noble v. Bioheart, Inc. US Stem Cell Clinics LLC, Aleiandro Perez, ARNP, and Shareen Greenbaum, M.D. During the year ended December 31, 2016, both matters settled by the Company’s insurance policy with no additional cost to the Company. On February 8, 2016, a collection lawsuit was filed in Broward County, specifically Roche Diagnostics Corp. v. U.S. Stem Cell, Inc., demanding judgement against the Company for an aggregate of $42,246 plus interest and costs for alleged unpaid product. During the year ended December 31, 2016, the Company settled all matters for a net payment of $8,500. On August 30 th On November 7, 2016, the Board of Directors, formed a separate committee to review and advise on improper activities undertaken by Charles Hart both during his tenure as a member of the Board of Directors and subsequent to his termination from the Board of Directors, specifically during the ninety days following his termination in which he is still considered an affiliate of the Company. Charles Hart was a member of the Board of Directors of NorthStar and is, to our knowledge, no longer a Director but remains a Member of the closely held NorthStar Biotech Group, LLC. (See the Current Report on Form 8-K, filed with the Securities and Exchange Committee on August 2, 2016, reporting that on August 1, 2016, Charles Hart was removed as a member of the Board of Directors). The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of December 31, 2016 other then described above.

NOTE 13 - INCOME TAXES

NOTE 13 - INCOME TAXES	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 13 — INCOME TAXES The Company follows Accounting Standards Codification subtopic 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows: 2016 2015 Income taxes using U.S. federal statutory rate $ (703,931 ) $ (575,971 ) State income taxes, net of federal benefit (76,227 ) (47,571 ) Return to Provision adjustments 4,499 116,025 Stock Option Expirations5 - - Net Operating Loss adjustments - - Nontaxable Gain on Derivative Instrument (19,123 ) 8,101 Change in Valuation Allowance 790,174 493,123 Other 4,608 6,293 $ - $ - At December 31, 2016 and 2015, the significant components of the deferred tax assets (liabilities) are summarized below: 2016 2015 Deferred tax assets: Stock Based Compensation $ 5,253,166 $ 5,099,422 Net Operating Losses 36,939,801 36,323,004 Other 44,407 24,774 Total deferred tax assets 42,237,374 41,447,200 Deferred tax liabilities: - — Total deferred tax liabilities - — Valuation allowance 42,237,374 41,447,200 Net deferred tax assets $ - $ — As of December 31, 2016 and December 31, 2015, the Company had U.S. federal net operating loss carryforwards of approximately $98.2 million and $96.5 million, respectively, which expire at various dates from 2019 through 2036. These net operating loss carryforwards may be used to offset future taxable income and thereby reduce the Company’s U.S. federal income taxes. Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by section 382 of the Code, the Company’s net operating loss carryforwards may be significantly limited as to the amount of use in a particular years. In addition, all or a portion of the Company’s net operating loss carryforwards may expire unutilized. As of December 31, 2016 and December 31, 2015, the Company had net operating loss carryforwards for state income tax purposes of approximately $98.2 million and $96.5 million, respectively, which expire at various dates from 2019 through 2036. The Company has provided a full valuation allowance against its net deferred tax assets, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits of these assets will not be realized. The Company complies with the provisions of FASB ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10. The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The Company’s tax years generally remain open to examination for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense.

NOTE 14 - FAIR VALUE MEASUREMEN

NOTE 14 - FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 14 — FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity. As of December 31, 2016 and 2015, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 6 and 8 are that of volatility and market price of the underlying common stock of the Company. As of December 31, 2016 and 2015, the Company did not have any derivative instruments that were designated as hedges. The derivative liability as of December 31, 2016, in the amount of $297,156 has a level 3 classification. The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of December 31, 2016: Warrant Liability Debt Derivative Balance, December 31, 2014 $ 149,920 $ 591,351 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,097,379 Mark-to-market at December 31, 2015: (137,711 ) 122,616 Transfers out of Level 3 upon conversion and settlement of notes — (1,399,628 ) Balance, December 31, 2015 12,209 411,718 Total (gains) losses Initial fair value of debt derivative at note issuance — 618,946 Mark-to-market at December 31, 2016: (12,185 ) (44,059 ) Transfers out of Level 3 upon conversion or payoff of notes payable — (689,473 ) Balance, December 31, 2016 $ 24 $ 297,132 Net gain for the period included in earnings relating to the liabilities held at December 31, 2016 $ 12,185 $ 44,059 Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. During the year ended December 31, 2016, the Company’s stock price dropped 99% from December 31, 2015. As the stock price drops for each of the related derivative instruments, the value to the holder of the instrument generally decreases. Stock price is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. Decreases in expected volatility would generally result in a lower fair value measurement. A 10 percent change in pricing inputs and changes in volatilities and correlation factors would result in less than a $13,000 change in our Level 3 fair value.

NOTE 15 - SUBSEQUENT EVENTS

NOTE 15 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 15 — SUBSEQUENT EVENTS Northstar Biotech Group, LLC On August 30 th GACP Stem Cell Bank LLC. On March 3, 2017 On March 3, 2017 In conjunction with the Asset Sale and Lease Agreement and the Asset Purchase Agreement, on March 3, 2017 In conjunction with the Asset Sale and Lease Agreement, the Asset Purchase Agreement, and the Customer Purchase Agreement, on March 3, 2017 Subsequent stock issuances In January 2017, the Company issued an aggregate of 1,255,623 shares of its common stock in payment of services rendered and 45,531,246 shares of its common stock in settlement of convertible notes and accrued interest of $58,075 and $1,820, respectively. In February 2017, the Company issued an aggregate of 76,082,378 shares of its common stock in settlement of convertible notes and interest of $95,435 and $23,642, respectively. In March 2017, the Company issued 3,225,807 shares of its common stock in payment of $25,000 of legal services and an aggregate of 42,657,254 of its common stock in settlement of convertible notes and interest of $59,865 and $3,571, respectively. Stock Options On February 6, 2017, the Company issued 16,200,000 stock options to US Stem Cell Inc. employees.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis and business presentation U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise. On October 12, 2015, the Company amended its Articles of Incorporation to change its name from Bioheart, Inc. to U.S. Stem Cell, Inc. and to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of common stock. This amendment was approved and filed of record by the Florida Secretary of State on October 12, 2015, effective on October 19, 2015. FINRA has declared the Company’s 1-for-1,000 reverse stock split market effective as of November 4, 2015. In addition, the ticker symbol was BHRTD for 20 business days from November 4, 2015 at which point was changed to USRM. These financial statements have been retroactively restated to reflect the reverse stock split (see Note 10).
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from trainings are recognized when the training occurs. Any cash received as a deposit for trainings are recorded by the company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on vendor-specific objective evidence of fair value (VSOE). The multiple elements include stem cell banking, dose retrieval and yearly storage fees. At December 31, 2016 and 2015, the Company had deferred revenues of $198,432 and $71,961, respectively.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Receivables, Policy [Policy Text Block]	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2016 and 2015, allowance for doubtful accounts was $12,487 and $-0-, respectively.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.
Equity Method Investments, Policy [Policy Text Block]	Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company determined that there was no impairment on its long-lived assets during 2016 and 2015.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of derivative liability and stock compensation accounting versus tax differences.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income The Company does not have any items of comprehensive income in any of the periods presented.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of December 31, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: 2016 2015 Convertible notes payable 238,046,980 677,540 Options to purchase common stock 23,555,777 555,820 Warrants to purchase common stock 139,145 139,367 Totals 261,741,902 1,372,727
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2016, there were outstanding stock options to purchase 23,555,777 shares of common stock, 8,380,503 shares of which were vested. (See Note 11)
Stockholders' Equity, Policy [Policy Text Block]	Treasury Stock The Company uses the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of December 31, 2016, four customers represented 45%, 13%, 13% and 12%, respectively, representing an aggregate of 83% of the Company’s accounts receivable. As of December 31, 2015, three customers represented 32%, 18% and 16% respectively, representing an aggregate of 66% of the Company’s accounts receivable. For the year ended December 31, 2016, the Company’s revenues earned from the sale of products and services to one customer, a related party, were $487,710, which represented 16% of the Company’s revenues. For the year ended December 31, 2015, the Company’s revenues earned from sale of products and services did not include any customers representing 10% or more of the Company’s total revenues.
Reliance on Key Personnel and Consultants [Policy Text Block]	Reliance on Key Personnel and Consultants The Company has seven full-time employees and one part-time employee. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $919 and $10,000 for the years ended December 31, 2016 and 2015, respectively.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2016 and 2015, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2016 and 2015, the Company had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 7 and Note 9)
Reclassification, Policy [Policy Text Block]	Reclassification Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.

NOTE 1 - SIGNIFICANT ACCOUNTI24

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: 2016 2015 Convertible notes payable 238,046,980 677,540 Options to purchase common stock 23,555,777 555,820 Warrants to purchase common stock 139,145 139,367 Totals 261,741,902 1,372,727

NOTE 4 - PROPERTY AND EQUIPME25

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of December 31, 2016 and 2015 is summarized as follows: 2016 2015 Laboratory and medical equipment $ 342,218 $ 353,253 Furniture, fixtures and equipment 130,410 130,410 Computer equipment 48,788 48,788 Leasehold improvements 362,046 362,046 883,462 894,497 Less accumulated depreciation and amortization (862,493 ) (880,325 ) $ 20,969 $ 14,172

NOTE 5 - ACCRUED EXPENSES (Tabl

NOTE 5 - ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following as of December 31, 2016 and 2015: 2016 2015 Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 154,296 $ 64,199 Interest payable on notes payable 599,510 467,664 Vendor accruals and other 146,429 147,244 Employee commissions, compensation, etc. 4,537 47,644 $ 904,772 $ 726,751

NOTE 7 - NOTES PAYABLE (Tables)

NOTE 7 - NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Promissory notes payable were comprised of the following as of December 31, 2016 and 2015: 2016 2015 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams notes payable 384,972 384,972 Daniel James Management notes payable 7,940 75,000 Fourth Man, LLC notes payable 100,000 77,450 Magna Group notes payable 130,455 125,000 Power Up Lending Group notes payable 159,300 194,235 Equipment finance lease 3,727 4,777 Total notes payable 1,766,394 1,841,434 Less unamortized debt discount (103,479 ) (249,205 ) Total notes payable net of unamortized debt discount 1,662,915 1,592,229 Less current portion (680,336 ) (608,502 ) Long term portion $ 982,579 $ 983,727

NOTE 8 - RELATED PARTY TRANSA28

NOTE 8 - RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Officer and Director Notes 2016 2015 Note payable, Beverly Murphy $ 50,000 $ 50,000 Note payable, Mr. Tomas 81,420 252,250 Note payable, Mr. Tomas 375,000 375,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 - Note payable, Ms. Comella 221,865 287,772 Note payable, Ms. Comella 300,000 - Total $ 2,028,285 $ 1,465,022

NOTE 11 - STOCK OPTIONS AND W29

NOTE 11 - STOCK OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of options at December 31, 2016 and activity during the two years then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at January 1, 2015 66,933 $ 56.00 8.9 Granted 489,116 $ 1.98 10.0 Exercised — Forfeited/Expired (229 ) $ 5,103.28 Options outstanding at December 31, 2015 555,820 $ 6.43 9.6 Granted 23,000,000 $ 0.02 10.0 Exercised — Forfeited/Expired (43 ) $ 1,960.39 Options outstanding at December 31, 2016 23,555,777 $ 0.03 9.7 Options exercisable at December 31, 2016 8,380,503 $ 0.06 9.7 Available for grant at December 31, 2016 9,383,070
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following information applies to options outstanding and exercisable at December 31, 2016: Exercise Number Option Outstanding Options Average Remaining Contractual Life (years) Weighted Average Number Options Exercisable Weighted Average Exercise price $ 0.0196 22,850,000 9.72 $ 0.0196 7,850,000 $ 0.0196 0.15402 705,412 8.74 0.15402 530,213 0.15402 19.32 150 7.85 19.32 75 19.32 70.00 100 4.66 70.00 100 70.00 210.00 40 4.62 210.00 40 210.00 680.00 40 3.11 680.00 40 680.00 5,250.00 35 1.30 5,250.00 35 5,250.00 Total 23,555,777 9.69 $ 0.033 8,380,503 $ 0.05529
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of common stock purchase warrants at December 31, 2016 and activity during the two years ended December 31, 2016 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at January 1, 2015 150,620 $ 170.00 6.6 Issued 2,072 $ 19.98 8.18 Exercised - Expired (13,325 ) $ 24.00 Outstanding at December 31, 2015 139,367 $ 182.26 6.3 Issued - Exercised - Expired (222 ) $ 5,966.40 Outstanding at December 31, 2016 139,145 $ 173.03 5.5 Exercisable at December 31, 2016 135,600 $ 89.42 5.5
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following information applies to common stock purchase warrants outstanding and exercisable at December 31, 2016: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 6.0 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 5.1 $ 24.52 28,743 $ 24.62 $ 30.01 – $40.00 628 0.6 $ 40.00 628 $ 40.00 $ 40.01 - $50.00 6,253 2.9 $ 48.36 5,253 $ 48.41 $ 50.01 – $60.00 543 4.6 $ 60.00 543 $ 60.00 $ >60.00 7,870 3.3 $ 2,735.01 6,325 $ 1,524.67 139,145 5.5 $ 173.03 135,600 $ 89.42

NOTE 12 - COMMITMENTS AND CON30

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of December 31, 2016 are as follows: Period ending December 31, 2017 87,674 2018 87,674 2019 58,448 Total $ 233,796

NOTE 13 - INCOME TAXES (Tables)

NOTE 13 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows: 2016 2015 Income taxes using U.S. federal statutory rate $ (703,931 ) $ (575,971 ) State income taxes, net of federal benefit (76,227 ) (47,571 ) Return to Provision adjustments 4,499 116,025 Stock Option Expirations5 - - Net Operating Loss adjustments - - Nontaxable Gain on Derivative Instrument (19,123 ) 8,101 Change in Valuation Allowance 790,174 493,123 Other 4,608 6,293 $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	At December 31, 2016 and 2015, the significant components of the deferred tax assets (liabilities) are summarized below: 2016 2015 Deferred tax assets: Stock Based Compensation $ 5,253,166 $ 5,099,422 Net Operating Losses 36,939,801 36,323,004 Other 44,407 24,774 Total deferred tax assets 42,237,374 41,447,200 Deferred tax liabilities: - — Total deferred tax liabilities - — Valuation allowance 42,237,374 41,447,200 Net deferred tax assets $ - $ —

NOTE 14 - FAIR VALUE MEASUREM32

NOTE 14 - FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of December 31, 2016: Warrant Liability Debt Derivative Balance, December 31, 2014 $ 149,920 $ 591,351 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,097,379 Mark-to-market at December 31, 2015: (137,711 ) 122,616 Transfers out of Level 3 upon conversion and settlement of notes — (1,399,628 ) Balance, December 31, 2015 12,209 411,718 Total (gains) losses Initial fair value of debt derivative at note issuance — 618,946 Mark-to-market at December 31, 2016: (12,185 ) (44,059 ) Transfers out of Level 3 upon conversion or payoff of notes payable — (689,473 ) Balance, December 31, 2016 $ 24 $ 297,132 Net gain for the period included in earnings relating to the liabilities held at December 31, 2016 $ 12,185 $ 44,059

NOTE 1 - SIGNIFICANT ACCOUNTI33

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Oct. 12, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Stockholders' Equity Note, Stock Split	1-for-1,000
Deferred Revenue (in Dollars)		$ 198,432	$ 71,961
Allowance for Doubtful Accounts Receivable, Current (in Dollars)		$ 12,487	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)		23,555,777	555,820	66,933
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)		8,380,503
Research and Development Expense (in Dollars)		$ 919	$ 10,000
U.S. Stem Cell Clinic, LLC [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage		33.00%
Revenues (in Dollars)		$ 487,710	$ 182,922
Full-Time Employees [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Number of Employees		7
Part-Time Employees [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Number of Employees		1
Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		83.00%	66.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer One [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		45.00%	32.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Two [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		13.00%	18.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Three [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		13.00%	16.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Four [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		12.00%
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Customer One [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		16.00%
Minimum [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life		3 years
Maximum [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life		15 years

NOTE 1 - SIGNIFICANT ACCOUNTI34

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	261,741,902	1,372,727
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	238,046,980	677,540
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	23,555,777	555,820
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	139,145	139,367

NOTE 2 - GOING CONCERN AND MA35

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ (2,070,386)	$ (1,641,880)
Working Capital (Deficit)	$ (5,834,548)

NOTE 3 - INVESTMENTS (Details)

NOTE 3 - INVESTMENTS (Details) - USD ($)	12 Months Ended		208 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
NOTE 3 - INVESTMENTS (Details) [Line Items]
Payments for (Proceeds from) Investments	$ (175,000)	$ 10,000
Income (Loss) from Equity Method Investments	153,405	38,542
Investments	$ 67,544	89,139	$ 67,544
U.S. Stem Cell Clinic, LLC [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	33.00%		33.00%
Payments for (Proceeds from) Investments		59,714
Income (Loss) from Equity Method Investments	$ 153,405	38,542	$ 182,830
Proceeds from Equity Method Investment, Dividends or Distributions	175,000
Investments		89,139
Accounts Receivable, Net	12,713	5,946	$ 12,713
Revenues	$ 487,710	$ 182,922

NOTE 4 - PROPERTY AND EQUIPME37

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Gain (Loss) on Disposition of Property Plant Equipment	$ 500	$ 0

NOTE 4 - PROPERTY AND EQUIPME38

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Schedule of Property and Equipment [Abstract]
Laboratory and medical equipment	$ 342,218	$ 353,253
Furniture, fixtures and equipment	130,410	130,410
Computer equipment	48,788	48,788
Leasehold improvements	362,046	362,046
	883,462	894,497
Less accumulated depreciation and amortization	(862,493)	(880,325)
	$ 20,969	$ 14,172

NOTE 5 - ACCRUED EXPENSES (Deta

NOTE 5 - ACCRUED EXPENSES (Details) - USD ($)	Nov. 04, 2015	Oct. 07, 2015	Dec. 31, 2016	Dec. 31, 2015
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	3,411	34,522
Gain (Loss) on Extinguishment of Debt			$ 53,690	$ 2,620,233
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			2,464,294	67,944
Gain (Loss) on Extinguishment of Debt			$ 138,976	$ 144,669
Common Stock Issued in Settlement of Guarantor Fees [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)				24,353
Gain (Loss) on Extinguishment of Debt				$ 791,024
Debt Conversion, Converted Instrument, Amount				$ 961,124
Debt Instrument, Term				5 years
Extinguishment of Debt, Amount				$ 624,737
Relief of Accounts Payable [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt				$ 513,940

NOTE 5 - ACCRUED EXPENSES (De40

NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Schedule of Accrued Liabilities [Abstract]
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest	$ 154,296	$ 64,199
Interest payable on notes payable	599,510	467,664
Vendor accruals and other	146,429	147,244
Employee commissions, compensation, etc.	4,537	47,644
	$ 904,772	$ 726,751

NOTE 6 - STOCK PURCHASE AGREE41

NOTE 6 - STOCK PURCHASE AGREEMENT (Details) - USD ($)	Oct. 23, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
NOTE 6 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Stock Issued During Period, Value, New Issues		$ 60,000	$ 582,808
Stock Purchase Agreement [Member]
NOTE 6 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Stock Repurchase Program, Authorized Amount	$ 3,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Stock Repurchase Program, Period in Force	24 months
Purchase Commitment, Description	From time to time over the term of the Purchase Agreement, commencing on the trading day immediately following the date on which the initial registration statement was declared effective by the Securities and Exchange Commission (the “Commission”), the Company may provide the Investor with a draw down notice to purchase a specified dollar amount of Shares, with each draw down subject to certain limitations.The Company may not deliver any Draw Down Notice to the Investor if the Initial Purchase Price with respect to the Shares subject to such Draw Down Notice is less than $2.50 as of the date the applicable Draw Down Notice is received by the Investor (the “Draw Down Exercise Date”).The applicable Initial Purchase Price, the “Initial Purchase Price”, is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company’s common stock (the “VWAP”) during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date, (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date and (iii) the closing sale price for the Company’s common stock on the trading day immediately preceding the applicable Draw Down Exercise Date.
Stock Issued During Period, Shares, New Issues			7,852	12,000
Stock Issued During Period, Value, New Issues			$ 61,270
Stock Purchase Agreement, Magna Equities II, LLC [Member]
NOTE 6 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			87,812
Stock Issued During Period, Value, New Issues			$ 521,538

NOTE 7 - NOTES PAYABLE (Details

NOTE 7 - NOTES PAYABLE (Details)

Aug. 16, 2016USD ($)

Mar. 23, 2016USD ($)

Dec. 17, 2015USD ($)

Dec. 03, 2015USD ($)

Nov. 04, 2015USD ($)

Oct. 07, 2015USD ($)

Aug. 06, 2015

Jun. 01, 2015USD ($)

Jul. 31, 2015USD ($)

Mar. 31, 2016

Dec. 31, 2016USD ($)$ / shares

Dec. 31, 2015USD ($)

Dec. 12, 2015USD ($)shares

Oct. 25, 2010USD ($)

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Notes Payable

$ 1,766,394

$ 1,841,434

Debt Conversion, Original Debt, Amount

$ 5,860

$ 100,000

Derivative Liability, Current

297,156

423,927

Debt Instrument, Unamortized Discount

103,479

249,205

Gain (Loss) on Extinguishment of Debt

53,690

2,620,233

Amortization of Debt Discount (Premium)

675,650

818,404

Repayments of Notes Payable

386,347

266,047

Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Unamortized Discount

$ 169,072

240,522

Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Gain (Loss) on Extinguishment of Debt

$ 10,221

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

164.06%

Fair Value Assumptions, Risk Free Interest Rate

0.87%

Embedded Derivative Financial Instruments [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

232.12%

Minimum [Member] | Embedded Derivative Financial Instruments [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Fair Value Assumptions, Risk Free Interest Rate

0.51%

Fair Value Assumptions, Expected Term

69 days

Maximum [Member] | Embedded Derivative Financial Instruments [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Fair Value Assumptions, Risk Free Interest Rate

0.62%

Fair Value Assumptions, Expected Term

262 days

Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 980,000

Debt Instrument, Interest Rate, Stated Percentage

4.25%

Debt Instrument, Maturity Date

Jan. 11, 2018

Notes Payable

$ 980,000

$ 980,000

Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

8.00%

Number of Outstanding Notes Payable

2

2

Notes Payable

$ 384,972

$ 384,972

Debt Instrument, Payment Terms

payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.

payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.

Hunton & Williams Note #1 [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Notes Payable

$ 61,150

$ 61,150

Hunton & Williams Note #2 [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Notes Payable

$ 323,822

323,822

Asher Notes Payable [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 180,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Feb. 6, 2016

Notes Payable

$ 0

Amortization of Debt Issuance Costs

$ 15,000

Debt Instrument, Term

9 months

Debt Instrument, Convertible, Terms of Conversion Feature

The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

convertible into shares of common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the shares of common stock during the 10 trading day period prior to conversion.

Embedded Derivative, Fair Value of Embedded Derivative Liability

$ 211,575

Asher Notes Payable [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

151,000

Asher Notes Payable [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

180,000

Daniel James Management Notes Payable [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 75,000

$ 125,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

9.50%

Debt Instrument, Maturity Date

Mar. 9, 2017

Oct. 29, 2016

Notes Payable

$ 7,940

$ 75,000

Debt Instrument, Term

1 year

1 year

Debt Instrument, Convertible, Terms of Conversion Feature

The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

Embedded Derivative, Fair Value of Embedded Derivative Liability

$ 238,443

Derivative Liability, Current

120,263

Debt Instrument, Unamortized Discount

$ 1,483

Daniel James Management Notes Payable [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Embedded Derivative, Fair Value of Embedded Derivative Liability

139,691

Derivative Liability, Current

9,436

Daniel James Management Notes Payable [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

75,000

75,000

Daniel James Management Notes Payable [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

67,060

50,000

Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 100,000

$ 150,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Debt Instrument, Maturity Date

Sep. 19, 2017

Dec. 2, 2016

Notes Payable

$ 100,000

$ 77,450

Debt Instrument, Term

1 year

1 year

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into common stock, at holder’s option, at a 49% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion

The Notes are convertible into shares of common stock, at Fourth Man’s option, at a 47% discount to the lowest closing bid price of the common stock during the 10 trading day period prior to conversion.

Embedded Derivative, Fair Value of Embedded Derivative Liability

$ 216,050

Debt Conversion, Original Debt, Amount

77,450

Derivative Liability, Current

151,236

Debt Instrument, Unamortized Discount

53,503

Fourth Man, LLC Notes Payable [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Embedded Derivative, Fair Value of Embedded Derivative Liability

$ 356,225

Derivative Liability, Current

126,825

Fourth Man, LLC Notes Payable [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

75,000

Fourth Man, LLC Notes Payable [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 72,550

Fourth Man, LLC Notes Payable [Member] | Minimum [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Fourth Man, LLC Notes Payable [Member] | Maximum [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Magna Group Notes Payable [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 262,500

$ 110,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

12.00%

Debt Instrument, Maturity Date

Dec. 3, 2016

Aug. 1, 2016

Notes Payable

130,455

$ 125,000

Debt Instrument, Payment Terms

In the event the Company prepays the Note in full, the Company is required to pay off all principal at 140%, interest and any other amounts

Debt Instrument, Convertible, Terms of Conversion Feature

The Note is convertible into common stock, at Magna’s option, at the lower of I) 40% discount to the lowest sales price of the common stock during the 5 trading day period prior to conversion or ii) $0.70.

The convertible note is convertible at any time, in whole or in part, at Magna’s option into shares of the Company’s common stock at the lower of 60% of the lowest sale price of the Company’s common stock during five trading days preceding conversion date or $0.70 per share (subject to adjustment).

The convertible note is convertible at any time, in whole or in part, at Magna’s option into shares of the Company’s common stock at a the lower of i) 60% discount to the lowest trading price of the common stock during the 5 trading day period prior to conversion or ii) $0.70 per share.

Debt Conversion, Original Debt, Amount

257,045

$ 205,000

Debt Instrument, Unamortized Discount

$ 12,500

Debt Instrument, Description

The purchase agreement provides that Magna shall purchase from the Company on the closing date a senior convertible note with an initial principal amount of $110,000 for a purchase price of $100,000.

Proceeds from Convertible Debt

$ 250,000

100,000

Debt Instrument, Increase (Decrease), Other, Net

$ (15,000)

Debt Instrument, Original Issue Discount, Percentage

5.00%

Debt Instrument, Number of Shares Authorized to be Converted (in Shares) | shares

341,718

Magna Group Notes Payable [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Embedded Derivative, Fair Value of Embedded Derivative Liability

263,204

291,136

Derivative Liability, Current

136,460

164,600

Magna Group Notes Payable [Member] | Note Payable #1 [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 110,000

Magna Group Notes Payable [Member] | Note Payable #2 [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 262,500

Power Up Lending Group Notes Payable [Member] | Revenue Based Factoring Agreement [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 283,500

$ 276,000

$ 202,500

Debt Instrument, Payment Terms

Under the terms of the agreement, the Company is required to make daily payments equal to $1,350 for 210 business days

Under the terms of the agreement, the Company is required to make daily payments equal to $1,314 for 210 business days

Proceeds from Convertible Debt

$ 210,000

Debt Instrument, Fee Amount

2,000

$ 1,650

4,500

Proceeds from Issuance of Debt

200,000

$ 150,000

Net Proceeds from Issuance of Debt

82,896

Gain (Loss) on Extinguishment of Debt

(49,264)

$ (39,449)

Net Proceeds from Convertible Debt

$ 65,193

Power Up Lending Group Notes Payable [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Notes Payable

159,300

194,235

Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 243,000

Notes Payable

159,300

194,235

Debt Instrument, Payment Terms

Under the terms of the agreements, the Company is required to make daily payments equal to $1,378 for 147 business days.

Under the terms of the agreements, the Company is required to make daily payments equal to the greater of $1,464 or 20% of the Company’s daily cash or monetary sales receipts over the term of the agreements (ranging from 126 to 189 business days).

Debt Instrument, Unamortized Discount

48,493

51,164

Proceeds from Convertible Debt

$ 180,000

Debt Instrument, Fee Amount

$ 3,590

Interest Expense, Debt

44,226

Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member] | Revenue Based Factoring Agreement [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Net Proceeds from Issuance of Debt

53,642

Gain (Loss) on Extinguishment of Debt

(8,679)

Power Up Lending Group Notes Payable [Member] | Minimum [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Term

126 days

Interest Expense, Debt

27,007

Power Up Lending Group Notes Payable [Member] | Maximum [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Term

189 days

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 1,697,762

Debt Instrument, Maturity Date

Jun. 1, 2020

Notes Payable

1,472,762

Debt Instrument, Unamortized Discount

$ 368,615

240,521

Gain (Loss) on Extinguishment of Debt

1,169,058

Debt Instrument, Frequency of Periodic Payment

four semi-annual

Debt Instrument, Periodic Payment

$ 75,000

Debt Instrument, Date of First Required Payment

Dec. 31, 2015

Debt Instrument, Imputed Interest, Stated Percentage

5.00%

Amortization of Debt Discount (Premium)

78,864

49,229

Repayments of Notes Payable

150,000

75,000

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Principal [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Extinguishment of Debt, Amount

$ 1,500,000

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Interest [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Extinguishment of Debt, Amount

373,469

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Guarantor Fees [Member] | Notes Payable, Other Payables [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Extinguishment of Debt, Amount

$ 624,737

Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Amortization of Debt Discount (Premium)

596,786

$ 768,241

Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Embedded Derivative, Fair Value of Embedded Derivative Liability

297,132

Debt Instrument, Unamortized Discount

618,946

Proceeds from Convertible Debt

425,000

Interest Expense, Debt

$ 193,946

Fair Value Assumptions, Expected Dividend Rate

0.00%

Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Minimum [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Fair Value Assumptions, Expected Volatility Rate

178.42%

Fair Value Assumptions, Risk Free Interest Rate

0.45%

Fair Value Assumptions, Expected Term

288 days

Share Price (in Dollars per share) | $ / shares

$ 0.0145

Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Maximum [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Fair Value Assumptions, Expected Volatility Rate

213.94%

Fair Value Assumptions, Risk Free Interest Rate

0.69%

Fair Value Assumptions, Expected Term

1 year

Share Price (in Dollars per share) | $ / shares

$ 0.9342

NOTE 7 - NOTES PAYABLE (Detai43

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 03, 2015
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 1,766,394	$ 1,841,434
Less unamortized debt discount	(103,479)	(249,205)
Total notes payable net of unamortized debt discount	1,662,915	1,592,229
Less current portion	(680,336)	(608,502)
Long term portion	982,579	983,727
Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Less unamortized debt discount	(169,072)	(240,522)
Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	980,000	980,000
Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	384,972	384,972
Daniel James Management Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	7,940	75,000
Less unamortized debt discount	(1,483)
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	100,000	77,450
Less unamortized debt discount	(53,503)
Magna Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	130,455	125,000
Less unamortized debt discount			$ (12,500)
Power Up Lending Group Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	159,300	194,235
Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	159,300	194,235
Less unamortized debt discount	(48,493)	(51,164)
Equipment Finance Lease [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 3,727	$ 4,777

NOTE 8 - RELATED PARTY TRANSA44

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Nov. 09, 2016	Oct. 06, 2016	May 01, 2016	Apr. 07, 2016	Feb. 16, 2016	Feb. 12, 2016	Nov. 06, 2015	Nov. 04, 2015	Oct. 07, 2015	Oct. 02, 2015	Apr. 03, 2015	Oct. 03, 2014	Jul. 01, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Mar. 30, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013	Sep. 06, 2016	Aug. 01, 2013	Feb. 28, 2013	Feb. 29, 2012
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current																				$ 104,901	$ 106,505
Debt Conversion, Converted Instrument, Shares Issued (in Shares)								3,411	34,522
Debt Conversion, Original Debt, Amount								$ 5,860	$ 100,000
Gain (Loss) on Extinguishment of Debt																				$ 53,690	$ 2,620,233
Class of Warrant or Rights, Granted (in Shares)																				0	2,072
PercentageOfRevenuesToBeReceivedAsRoyalty	5.00%
Preferred Stock, Shares Authorized (in Shares)																				20,000,000	20,000,000
Notes Payable, Related Parties																				$ 2,028,285	$ 1,465,022
Repayments of Related Party Debt																				266,737	0
Notes Payable, Related Parties, Current																				2,290,285	1,727,022
Accounts Payable, Related Parties, Current																				104,458	104,089
Series A Preferred Stock [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Preferred Stock, Voting Rights																	modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock
Affiliated Entity [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Purchases from Related Party																				0
Accounts Payable, Related Parties, Current																				106,455	74,793
Related Party Transaction, Description of Transaction			The agreement is for 12 months and renewable for 6 month periods. Compensation is at $250 per hour or, at the Company’s discretion, in shares of the Company’s common stock
U.S. Stem Cell Clinic, LLC [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount							$ 30,000
Debt Instrument, Interest Rate, Stated Percentage							4.00%
Debt Instrument, Maturity Date							Nov. 3, 2017
Director [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)								270,800
Debt Conversion, Original Debt, Amount								$ 465,200
Immediate Family Member of Management or Principal Owner [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Purchases from Related Party																					242,271
Settlement of Related Party Advances and Outstanding Accounts Payable [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)								3,411
Debt Conversion, Original Debt, Amount								$ 5,860
Settlement of Related Party Advances and Outstanding Accounts Payable [Member] | Officers and Directors [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)					14,606	14,606
Debt Conversion, Original Debt, Amount					$ 10,000	$ 10,000
Gain (Loss) on Extinguishment of Debt					$ 3,427	$ 3,427
Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)															3,916	8,772						10,000
Debt Conversion, Original Debt, Amount															$ 85,447	$ 100,000						$ 210,000
Debt Instrument, Face Amount																										$ 544,267
Debt Instrument, Payment Terms																	Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012).		agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
Class of Warrant or Rights, Granted (in Shares)																	15,000	5,000
Debt Instrument, Debt Default, Description of Violation or Event of Default																	entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
PercentageOfRevenuesToBeReceivedAsRoyalty																	8.00%
Debt Instrument, Interest Rate, Stated Percentage																	12.85%								7.00%
Notes Payable, Related Parties																				$ 262,000	$ 262,000
Notes Payable, Other Payables [Member] | Affiliated Entity [Member] | Series A Preferred Stock [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)																						5,000,000
Stock Issued During Period, Value, Other																						$ 274,050
Notes Payable, Other Payables [Member] | Affiliated Entity [Member] | Series A Preferred Stock [Member] | Settlement of Forbearance Agreement, Penalty [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)																						15,000,000
Notes Payable, Other Payables [Member] | Director [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																				7.00%	7.00%
Notes Payable, Related Parties																				$ 50,000	$ 50,000
Debt Instrument, Maturity Date																				Oct. 15, 2015	Oct. 15, 2015
Interest [Member] | Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		848,490		57,778						4,156	1,363	515		275
Debt Conversion, Original Debt, Amount		$ 12,705		$ 12,705						$ 12,705	$ 12,635	$ 12,705		$ 12,635
Debt Conversion, Converted Instrument, Amount				$ 12,705
Note Payable #1 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																						5.00%
Notes Payable, Related Parties																				$ 81,420	$ 252,250
Repayments of Related Party Debt																				170,830	79,104
Note Payable #1 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount													$ 300,000
Debt Instrument, Interest Rate, Stated Percentage													5.00%
Notes Payable, Related Parties																				221,865	287,772
Debt Instrument, Maturity Date													Jan. 1, 2015
Repayments of Related Party Debt																				65,907	11,693
Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																								$ 375,000
Debt Instrument, Interest Rate, Stated Percentage																								5.00%
Notes Payable, Related Parties																				375,000	375,000
Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																							$ 300,000
Debt Instrument, Interest Rate, Stated Percentage																							5.00%
Notes Payable, Related Parties																				300,000	0
Note Payable #3 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount													$ 500,000
Debt Instrument, Interest Rate, Stated Percentage													5.00%
Notes Payable, Related Parties																				500,000	500,000
Debt Instrument, Maturity Date													Jan. 1, 2015
Note Payable #4 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																							$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																							5.00%
Notes Payable, Related Parties																				500,000	$ 0
Notes Payable, Related Parties, Current																				$ 500,000

NOTE 8 - RELATED PARTY TRANSA45

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Notes Payable - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 2,028,285	$ 1,465,022
Ms. Murphy [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	50,000	50,000
Note Payable #1 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	81,420	252,250
Note Payable #1 [Member] | Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	221,865	287,772
Note Payable #2 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	375,000	375,000
Note Payable #2 [Member] | Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	300,000	0
Note Payable #3 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	500,000
Note Payable #4 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 500,000	$ 0

NOTE 9 - DERIVATIVE LIABILITI46

NOTE 9 - DERIVATIVE LIABILITIES (Details) - USD ($)	Oct. 01, 2012	Sep. 21, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)			0	2,072
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 173.03	$ 182.26	$ 170
Embedded Derivative Financial Instruments [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			$ 12,185
Embedded Derivative Financial Instruments [Member] | Warrant [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net (in Dollars)			$ 24
Fair Value Assumptions, Expected Dividend Rate			0.00%
Fair Value Assumptions, Expected Volatility Rate			232.12%
Fair Value Assumptions, Risk Free Interest Rate			1.93%
Fair Value Assumptions, Expected Term			5 years 9 months
Derivative, Gain (Loss) on Derivative, Net (in Dollars)				$ 137,710
Embedded Derivative Financial Instruments [Member] | Notes Payable, Other Payables [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net (in Dollars)			$ 297,132
Fair Value Assumptions, Expected Dividend Rate			0.00%
Fair Value Assumptions, Expected Volatility Rate			232.12%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			$ 44,059	$ 122,615
Fair Value of Common Stock (in Dollars per share)			$ 0.0019
Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)	15,000	5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 14
Warrants, Term of Warrants	10 years
Minimum [Member] | Embedded Derivative Financial Instruments [Member] | Notes Payable, Other Payables [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.51%
Fair Value Assumptions, Expected Term			69 days
Maximum [Member] | Embedded Derivative Financial Instruments [Member] | Notes Payable, Other Payables [Member]
NOTE 9 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.62%
Fair Value Assumptions, Expected Term			262 days

NOTE 10 - STOCKHOLDERS' EQUITY

NOTE 10 - STOCKHOLDERS' EQUITY (Details) - USD ($)	Oct. 06, 2016	Apr. 07, 2016	Feb. 16, 2016	Feb. 12, 2016	Nov. 04, 2015	Oct. 12, 2015	Oct. 07, 2015	Oct. 02, 2015	Aug. 17, 2015	Apr. 03, 2015	Mar. 19, 2015	Oct. 03, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 23, 2014	Dec. 31, 2012	Aug. 17, 2012
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized																		20,000,000	20,000,000
Preferred Stock, Shares Issued																		20,000,000	20,000,000
Stockholders' Equity, Reverse Stock Split						1-for-1,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)																		$ 0.001	$ 0.001
Adjustments to Additional Paid in Capital, Stock Split (in Dollars)																				$ 580,852
Debt Conversion, Converted Instrument, Shares Issued					3,411		34,522
Debt Conversion, Original Debt, Amount (in Dollars)					$ 5,860		$ 100,000
Stock Repurchased During Period, Shares																		10,250
Treasury Stock Acquired, Average Cost Per Share (in Dollars per share)																		$ 2.41
Treasury Stock, Shares, Retired																		95,461
Gain (Loss) on Extinguishment of Debt (in Dollars)																		$ 53,690	$ 2,620,233
Stock Issued During Period, Value, New Issues (in Dollars)																		60,000	582,808
Stock Issued During Period, Shares, Settlement of Litigation											6,650
Gain (Loss) Related to Litigation Settlement (in Dollars)																		$ 0	$ (59,850)
Class of Warrant or Rights, Granted																		0	2,072
Stock Purchase Agreement, Magna Equities II, LLC [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																			87,812
Stock Issued During Period, Value, New Issues (in Dollars)																			$ 521,538
Stock Purchase Agreement [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)																						$ 0.001
Stock Issued During Period, Shares, New Issues																			7,852	12,000
Stock Issued During Period, Value, New Issues (in Dollars)																			$ 61,270
Class of Warrant or Rights, Granted																			1,444
Series A Convertible Preferred Stock [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized																							20,000,000	5,000,000
Preferred Stock, Voting Rights									Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities												the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders
Preferred Stock, Shares Issued																					20,000,000
Director [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					270,800
Debt Conversion, Original Debt, Amount (in Dollars)					$ 465,200
Settlement of Related Party Advances and Outstanding Accounts Payable [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					3,411
Debt Conversion, Original Debt, Amount (in Dollars)					$ 5,860
Settlement of Related Party Advances and Outstanding Accounts Payable [Member] | Officers and Directors [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			14,606	14,606
Debt Conversion, Original Debt, Amount (in Dollars)			$ 10,000	$ 10,000
Gain (Loss) on Extinguishment of Debt (in Dollars)			$ 3,427	$ 3,427
Common Stock [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Repurchased During Period, Shares																		10,250	85,211
Treasury Stock Acquired, Average Cost Per Share (in Dollars per share)																		$ 0.76	$ 2.61
Stock Issued During Period, Shares, New Issues																		19,913,708	95,664
Stock Issued During Period, Value, New Issues (in Dollars)																		$ 19,914	$ 96
Stock Issued During Period, Shares, Settlement of Litigation																			6,650
Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued														3,916	8,772						10,000
Debt Conversion, Original Debt, Amount (in Dollars)														$ 85,447	$ 100,000						$ 210,000
Class of Warrant or Rights, Granted																15,000	5,000
Interest [Member] | Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	848,490	57,778						4,156		1,363		515	275
Debt Conversion, Original Debt, Amount (in Dollars)	$ 12,705	$ 12,705						$ 12,705		$ 12,635		$ 12,705	$ 12,635
Common Stock Issued in Settlement of Accounts Payable and Accrued Expenses [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																		1,558,026	62,425
Debt Conversion, Original Debt, Amount (in Dollars)																			$ 211,546
Gain (Loss) on Extinguishment of Debt (in Dollars)																		$ 138,976	144,669
Common Stock Issued in Settlement of Guarantor Fees [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt (in Dollars)																			$ 791,024
Stock Issued During Period, Shares, Other																			24,353
Stock Issued During Period, Value, Other (in Dollars)																			$ 961,125
Fair Value, Inputs, Level 3 [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																		102,901,904
Fair Value, Inputs, Level 3 [Member] | Embedded Derivative Financial Instruments [Member] | Notes Payable, Other Payables [Member]
NOTE 10 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																			763,434
Debt Conversion, Original Debt, Amount (in Dollars)																		$ 497,312	$ 949,017
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3 (in Dollars)																		$ (689,473)	$ (1,399,628)

NOTE 11 - STOCK OPTIONS AND W48

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - USD ($)

Sep. 19, 2016

Apr. 18, 2016

Nov. 02, 2015

Aug. 24, 2015

Feb. 02, 2015

Aug. 01, 2014

Dec. 31, 2016

Dec. 31, 2015

Sep. 16, 2016

Aug. 04, 2014

Dec. 31, 2013

Apr. 01, 2013

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

23,000,000

489,116

Share-based Compensation (in Dollars)

$ 410,002

$ 1,152,195

Class of Warrant or Rights, Granted (in Shares)

0

2,072

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 173.03

$ 182.26

$ 170

Gain (Loss) on Extinguishment of Debt (in Dollars)

$ 53,690

$ 2,620,233

Employee Stock Option [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation (in Dollars)

410,385

$ 1,156,435

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)

$ 438,472

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

1 year 120 days

Employee Stock Option [Member] | Key Employees [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

150,000

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 0.15402

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)

$ 10,928

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

184.48%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.54%

Employee Stock Option [Member] | Officers, Directors and Key Employees [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

22,850,000

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 0.0196

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)

$ 347,706

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

213.30%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.22%

Employee Stock Option [Member] | Director [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

7,000

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 11.16

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)

$ 121,735

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

142.65%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.68%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vesting immediately

Employee Stock Option [Member] | Officer [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

467,016

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 1.713

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)

$ 738,405

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

160.66%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.57%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vesting immediately

Employee Stock Option [Member] | Officers [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

15,000

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 6.24

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)

$ 23,512

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

160.66%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.93%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vesting over four years on each anniversary

Bioheart 2013 Omnibus Equity Compensation Plan [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

500,000,000

25,000,000

100,000

50,000

Options Modified [Member] | Employee Stock Option [Member] | Key Employees [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

555,433

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 0.15402

Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)

$ 934

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

184.48%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

0.22%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

1.78%

Options Issued to Consultant [Member] | Employee Stock Option [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

100

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 5.31

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)

$ 347

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

129.01%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.39%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vesting immediately

Convertible Debt [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

628

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 40

Warrants, Term of Warrants

3 years

Warrants, Fair Value of Warrants, Granted (in Dollars)

$ 14,886

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

164.06%

Fair Value Assumptions, Risk Free Interest Rate

0.87%

Gain (Loss) on Extinguishment of Debt (in Dollars)

$ 10,221

Share-based Compensation Award, Tranche Two [Member] | Employee Stock Option [Member] | Officers, Directors and Key Employees [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares)

15,000,000

Share-based Compensation Award, Tranche One [Member] | Employee Stock Option [Member] | Officers, Directors and Key Employees [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares)

7,850,000

Minimum [Member] | Options Modified [Member] | Employee Stock Option [Member] | Key Employees [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

1.71

Maximum [Member] | Options Modified [Member] | Employee Stock Option [Member] | Key Employees [Member]

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 7,688.83

NOTE 11 - STOCK OPTIONS AND W49

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Option Activity - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Option Activity [Abstract]
Options Outstanding	555,820		66,933
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 6.43		$ 56
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 255 days	9 years 219 days	8 years 328 days
Options exercisable	8,380,503
Options exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 0.06
Options exercisable, Weighted-Average Remaining Contractual Term	9 years 255 days
Available for grant	9,383,070
Options Granted	23,000,000	489,116
Options Granted, Weighted-Average Exercise Price (in Dollars per share)	$ 0.02	$ 1.98
Options Granted, Weighted-Average Remaining Contractual Term	10 years	10 years
Options Exercised	0	0
Options Forfeited/Expired	(43)	(229)
Options Forfeited/Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 1,960.39	$ 5,103.28
Options Outstanding	23,555,777	555,820
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 0.03	$ 6.43

NOTE 11 - STOCK OPTIONS AND W50

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Options Outstanding and Exercisable by Exercise Price Range	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 251 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.033
Options Outstanding (in Shares) | shares	23,555,777
Options Exercisable (in Shares) | shares	8,380,503
Options Exercisable, Weighted-Average Exercise Price	$ 0.05529
Options, $0.0196 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.0196
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 262 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.0196
Options Outstanding (in Shares) | shares	22,850,000
Options Exercisable (in Shares) | shares	7,850,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0196
Options, $0.15402 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.15402
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 270 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.15402
Options Outstanding (in Shares) | shares	705,412
Options Exercisable (in Shares) | shares	530,213
Options Exercisable, Weighted-Average Exercise Price	$ 0.15402
Options, $19.32 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 19.32
Options Outstanding, Weighted-Average Remaining Contractual Term	7 years 310 days
Options Outstanding, Weighted-Average Exercise Price	$ 19.32
Options Outstanding (in Shares) | shares	150
Options Exercisable (in Shares) | shares	75
Options Exercisable, Weighted-Average Exercise Price	$ 19.32
Options, $70.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 70
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years 240 days
Options Outstanding, Weighted-Average Exercise Price	$ 70
Options Outstanding (in Shares) | shares	100
Options Exercisable (in Shares) | shares	100
Options Exercisable, Weighted-Average Exercise Price	$ 70
Options, $210.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 210
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years 226 days
Options Outstanding, Weighted-Average Exercise Price	$ 210
Options Outstanding (in Shares) | shares	40
Options Exercisable (in Shares) | shares	40
Options Exercisable, Weighted-Average Exercise Price	$ 210
Options, $680.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 680
Options Outstanding, Weighted-Average Remaining Contractual Term	3 years 40 days
Options Outstanding, Weighted-Average Exercise Price	$ 680
Options Outstanding (in Shares) | shares	40
Options Exercisable (in Shares) | shares	40
Options Exercisable, Weighted-Average Exercise Price	$ 680
Options, $5,250.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 5,250
Options Outstanding, Weighted-Average Remaining Contractual Term	1 year 109 days
Options Outstanding, Weighted-Average Exercise Price	$ 5,250
Options Outstanding (in Shares) | shares	35
Options Exercisable (in Shares) | shares	35
Options Exercisable, Weighted-Average Exercise Price	$ 5,250

NOTE 11 - STOCK OPTIONS AND W51

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Activity - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Warrants Activity [Abstract]
Warrants Outstanding	139,367		150,620
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 182.26		$ 170
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 6 months	6 years 109 days	6 years 219 days
Warrants Exercisable	135,600
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 89.42
Warrants Exercisable, Weighted-Average Remaining Contractual Term	5 years 6 months
Warrants Issued	0	2,072
Warrants Issued, Weighted-Average Exercise Price (in Dollars per share)		$ 19.98
Warrants Issued, Weighted-Average Remaining Contractual Term		8 years 65 days
Warrants Exercised	0	0
Warrants Expired	(222)	(13,325)
Warrants Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 5,966.40	$ 24
Warrants Outstanding	139,145	139,367
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 173.03	$ 182.26

NOTE 11 - STOCK OPTIONS AND W52

NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	$ 173.03	$ 182.26		$ 170
Warrants Outstanding (in Shares)	139,145	139,367		150,620
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 6 months	6 years 109 days	6 years 219 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 173.03
Warrants Exercisable (in Shares)	135,600
Warrants Exercisable, Weighted-Average Exercise Price	$ 89.42
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	94,108
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years
Warrants Outstanding, Weighted-Average Exercise Price	$ 15.54
Warrants Exercisable (in Shares)	94,108
Warrants Exercisable, Weighted-Average Exercise Price	$ 15.54
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	29,743
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 36 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 24.52
Warrants Exercisable (in Shares)	28,743
Warrants Exercisable, Weighted-Average Exercise Price	$ 24.62
Class of Warrants or Rights, Exercise Price Range, $30.01-$40.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	628
Warrants Outstanding, Weighted-Average Remaining Contractual Term	219 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 40
Warrants Exercisable (in Shares)	628
Warrants Exercisable, Weighted-Average Exercise Price	$ 40
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	6,253
Warrants Outstanding, Weighted-Average Remaining Contractual Term	2 years 328 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 48.36
Warrants Exercisable (in Shares)	5,253
Warrants Exercisable, Weighted-Average Exercise Price	$ 48.41
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	543
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 219 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 60
Warrants Exercisable (in Shares)	543
Warrants Exercisable, Weighted-Average Exercise Price	$ 60
Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	$ 60
Warrants Outstanding (in Shares)	7,870
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years 109 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 2,735.01
Warrants Exercisable (in Shares)	6,325
Warrants Exercisable, Weighted-Average Exercise Price	$ 1,524.67
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	0.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	20.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $30.01-$40.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	30.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	40.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	50.01
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	20
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	30
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $30.01-$40.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	40
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	50
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 11 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	$ 60

NOTE 12 - COMMITMENTS AND CON53

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) - USD ($)

Mar. 01, 2017

Feb. 06, 2017

Nov. 09, 2016

Sep. 06, 2016

Aug. 30, 2016

Feb. 08, 2016

Nov. 02, 2015

Jul. 28, 2015

Mar. 19, 2015

Jul. 28, 2014

Jul. 31, 2013

Nov. 02, 2015

Jun. 30, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

23,000,000

489,116

Royalty Agreement, Term

25 years

Royalty Revenue

$ 75,000

PercentageOfRevenuesToBeReceivedAsRoyalty

5.00%

Stock Issued During Period, Shares, Settlement of Litigation (in Shares)

6,650

Loss Contingency, Damages Sought, Value

$ 42,246

Payments for Legal Settlements

$ 8,500

Subsequent Event [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

16,200,000

Chief Executive Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

10,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 0.0196

Building [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Lease Expiration Date

Aug. 31, 2019

Northstar Claims [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Loss Contingency, Damages Sought

Northstar Biotech Group, LLC (“NorthStar”) filed suit against the Company seeking a declaratory judgment as to whether its 20,000,000 Series A Preferred Shares were the subject of the Company’s reverse stock split effective November 4, 2015.

Northstar Claims [Member] | Subsequent Event [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

PercentageOfRevenuesToBeReceivedAsRoyalty

10.00%

Stockholders' Equity, Other Shares (in Shares)

10,000,000

Number of Directors

2

Equity Method Investment, Ownership Percentage

5.00%

Annual Salary [Member] | Chief Executive Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 525,000

Annual Salary [Member] | Chief Scientific Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 250,000

Incentive Bonus [Member] | Chief Executive Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 500,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

291,885

10,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 1.713

Accrued Bonuses

$ 500,000

Related Party Transaction, Rate

5.00%

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

The cash bonus may be paid in the form a six month promissory note.

Incentive Bonus [Member] | Chief Scientific Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

5,000,000

175,131

5,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

4 years

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 0.0196

$ 1.713

Accrued Bonuses

$ 300,000

Related Party Transaction, Rate

5.00%

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

The cash bonus may be paid in the form a six month promissory note.

Minimum [Member] | Incentive Bonus [Member] | Chief Executive Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 150,000

Minimum [Member] | Incentive Bonus [Member] | Chief Scientific Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 100,000

Maximum [Member] | Incentive Bonus [Member] | Chief Executive Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 500,000

Maximum [Member] | Incentive Bonus [Member] | Chief Scientific Officer [Member]

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 300,000

$ 300,000

NOTE 12 - COMMITMENTS AND CON54

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases	Dec. 31, 2016USD ($)
Schedule of Future Minimum Rental Payments for Operating Leases [Abstract]
2,017	$ 87,674
2,018	87,674
2,019	58,448
Total	$ 233,796

NOTE 13 - INCOME TAXES (Details

NOTE 13 - INCOME TAXES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
NOTE 13 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	$ 98.2	$ 96.5
Annual Limit of Corporation to Reduce Tax Liability	Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability
Operating Loss Carryforwards, Limitations on Use	If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by section 382 of the Code, the Company’s net operating loss carryforwards may be significantly limited as to the amount of use in a particular years.
Domestic Tax Authority [Member] | Minimum [Member]
NOTE 13 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards, Expiration Year	2,019
Domestic Tax Authority [Member] | Maximum [Member]
NOTE 13 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards, Expiration Year	2,036
State and Local Jurisdiction [Member]
NOTE 13 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	$ 98.2	$ 96.5
State and Local Jurisdiction [Member] | Minimum [Member]
NOTE 13 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards, Expiration Year	2,019
State and Local Jurisdiction [Member] | Maximum [Member]
NOTE 13 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards, Expiration Year	2,036

NOTE 13 - INCOME TAXES (Detai56

NOTE 13 - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Income taxes using U.S. federal statutory rate	$ (703,931)	$ (575,971)
State income taxes, net of federal benefit	(76,227)	(47,571)
Return to Provision adjustments	4,499	116,025
Stock Option Expirations5	0	0
Net Operating Loss adjustments	0	0
Nontaxable Gain on Derivative Instrument	(19,123)	8,101
Change in Valuation Allowance	790,174	493,123
Other	4,608	6,293
	$ 0	$ 0

NOTE 13 - INCOME TAXES (Detai57

NOTE 13 - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Stock Based Compensation	$ 5,253,166	$ 5,099,422
Net Operating Losses	36,939,801	36,323,004
Other	44,407	24,774
Total deferred tax assets	42,237,374	41,447,200
Total deferred tax liabilities	0	0
Valuation allowance	42,237,374	41,447,200
Net deferred tax assets	$ 0	$ 0

NOTE 14 - FAIR VALUE MEASUREM58

NOTE 14 - FAIR VALUE MEASUREMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Derivative Liability, Current	$ 297,156	$ 423,927
Percentage of Stock Price Decrease	(99.00%)
Fair Value Measurements, Valuation Processes, Description	A 10 percent change in pricing inputs and changes in volatilities and correlation factors would result in less than a $13,000 change in our Level 3 fair value.

NOTE 14 - FAIR VALUE MEASUREM59

NOTE 14 - FAIR VALUE MEASUREMENT (Details) - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - Fair Value, Inputs, Level 3 [Member] - Embedded Derivative Financial Instruments [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 12,209	$ 149,920
Net gain for the period included in earnings relating to the liabilities held at December 31, 2016	12,185
Initial fair value of derivative		0
Mark-to-market	(12,185)	(137,711)
Transfers out of Level 3	0
Balance	24	12,209
Notes Payable, Other Payables [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	411,718	591,351
Net gain for the period included in earnings relating to the liabilities held at December 31, 2016	44,059
Initial fair value of derivative	618,946	1,097,379
Mark-to-market	(44,059)	122,616
Transfers out of Level 3	(689,473)	(1,399,628)
Balance	$ 297,132	$ 411,718

NOTE 15 - SUBSEQUENT EVENTS (De

NOTE 15 - SUBSEQUENT EVENTS (Details) - USD ($)	Mar. 03, 2017	Mar. 01, 2017	Feb. 06, 2017	Nov. 09, 2016	Nov. 04, 2015	Oct. 07, 2015	Mar. 31, 2017	Feb. 28, 2017	Jan. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
NOTE 15 - SUBSEQUENT EVENTS (Details) [Line Items]
PercentageOfRevenuesToBeReceivedAsRoyalty				5.00%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)					3,411	34,522
Debt Conversion, Original Debt, Amount					$ 5,860	$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)										23,000,000	489,116
Subsequent Event [Member]
NOTE 15 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)							3,225,807		1,255,623
Debt Conversion, Converted Instrument, Shares Issued (in Shares)							42,657,254	76,082,378	45,531,246
Stock Issued During Period, Value, Issued for Services							$ 25,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)			16,200,000
Subsequent Event [Member] | Northstar Claims [Member]
NOTE 15 - SUBSEQUENT EVENTS (Details) [Line Items]
Stockholders' Equity, Other Shares (in Shares)		10,000,000
PercentageOfRevenuesToBeReceivedAsRoyalty		10.00%
Number of Directors		2
Equity Method Investment, Ownership Percentage		5.00%
Principal [Member] | Subsequent Event [Member]
NOTE 15 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount							59,865	$ 95,435	$ 58,075
Interest [Member] | Subsequent Event [Member]
NOTE 15 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount							$ 3,571	$ 23,642	$ 1,820
GACP Stem Cell Bank, LLC [Member] | Subsequent Event [Member]
NOTE 15 - SUBSEQUENT EVENTS (Details) [Line Items]
Sale Leaseback Transaction, Lease Terms	Simultaneous with the sale of the Equipment Assets, the Company leased back the Equipment Assets for a term of three years
Sale Leaseback Transaction, Monthly Rental Payments	$ 20,000
Equipment Assets [Member] | GACP Stem Cell Bank, LLC [Member] | Subsequent Event [Member]
NOTE 15 - SUBSEQUENT EVENTS (Details) [Line Items]
Sale Leaseback Transaction, Net Book Value	400,000
Non-Equipment Assets [Member] | GACP Stem Cell Bank, LLC [Member] | Subsequent Event [Member]
NOTE 15 - SUBSEQUENT EVENTS (Details) [Line Items]
Sale Leaseback Transaction, Net Book Value	$ 50,000